Life Sciences Company Profileold.iss.it/binary/biot/cont/all.1200910092.pdf · business management...

Company ProfileChina Europe

PartneringLife Sciences

3 i Consulting Srl.



Country Italy

Website www.bioinnovit.comEmail

Address Via Val Trompia 108,

00141 Roma

Phone +39 3477829440Fax +39 06233231988

Strategic Advisor for partnering, technology transfer, funding and start-up launch.

3i Consulting Srl. Is a strategic consultancy specialized in life sciences and specifically in all aspects of technology transfer and strategic partnering. Clients’ portfolio include public research institutions, universities, scientists and research groups, small and big Pharma companies, established biotechnology companies & startups, academic spin-offs, venture capital companies and VC funds invested and investing in life sciences.

3i Consulting Srl. provides the following services to the life sciences community:

- intellectual property protection, management & marketing- strategic partnering and technology transfer services- scouting and due diligence services for industry and finance partners To better achieve its mission 3i Consulting, through its affiliated web properties holding 3iC LLC, has launched Bioinnovit.com a web based Life Sciences Exchange ( LSX) and Online Technology Transfer Office (OTTO) offering the worldwide life sciences community a meeting point and tools for a variety of Technology Transfer events.

3i Consulting Srl. and 3iC LLC have been founded by Giovan Battista Cozzone, a biotechnology startup and venture capital specialist.

Technology/Product AdvantageA personalized service approach combined with the exposure that two highly trafficked web site partnering and funding exchanges offer.

Product/Service is currently being manufactured

AchievementsDeveloped from stratch (and has currently under management) the technology transfer and industrial liaison offices of Italian NIH and of Universities of Urbino & Perugia. Over 150 patented inventions under management at present.

Founded 1977

One-line Business Description

Business Activity

Key CustomersItalian NIH, University of Urbino, University of Perugia, University of Camerino, University of Ancona, EU biotech SMEs

Key PartnershipsItalian NIH, University of Urbino, Università di Perugia

Key CompetitorsUTEK, BTG plc., Pharmalicensing, Independent professionals

Dr Giovanni Cozzone, Chief Executive OfficerEmail: [email protected]: +39 347829440

Presenter

1 Life Sciences Partnering China Europe, 18-19 September 2006

3 i Consulting Srl.



Other informationThe company has no structural overheads.

Financing Sought/Investment Plan3 i Consulting Srl. is seeking Expansion / Development financing to the amount of 0.25 M Euro in exchange for 20% of the company shares or 3-year convertible bond at 2,5%; conversion at 30% equity or repayment + 10% equity kicker .

The investment capital will be used to expand service operations by hiring a technology transfer specialist in North Italy, a home-based back-office staff, and to boost capacity & functionality of web based partnering & financing exchanges. Its goal is to evolve from a personal consultancy practice into a full service company with web based revenue generation.

3 i Consulting Srl. is seeking partnership for Other, Product development and Distribution.

3 i Consulting is seeking a corporate or financial partner to inject investments funds in order to expand service and web based operations.

Partnership Sought

Management TeamDr Giovanni Cozzone, Chief Executive Officer

Cozzone is a corporate finance, technology transfer and strategic partnering specialist with over 25 years of business experience encompassing large corporations, start-ups and venture capital firms. His professional experience includes 8 years as an executive in a global pharmaceutical company and 15 years in several Italian and International biotechnology start-ups which he founded and managed as CEO. Skilled at creating and developing fast-paced organizations, he has international experience on both sides of the Atlantic and a solid network in European life science business and finance sectors. Currently he heads, in the role of expert advisor to the Board, the technology transfer and industrial collaboration activities of several public research institutions and universities in central-northern Italy and has under management a patent portofolio consisting of over 150 international patent applications and patents. He is a member of the Board of Italian several biotech start-ups and European Research Consortia with responsibility for business management (among others, AVIP, a €10 million integrated project; Neuropromise, a €11.4 million integrated project) and has under business management or IP management over 50 large and small FP funded projects.

Dr Maurizio Fiani, Chief Financial OfficerDr. Fiani is a CPA and is the controller for 3 i Consulting. Dr. Fiani has held the controller position in several large R&D public research consortiums in Italy.

ShareholdersManagement team 100%

Key Financials Thousand of Euro

2004 2005 2006 2007 2008120100 180 300Turnover7565 100 180EBIT1010 500 500Equity00 2 4Employment

Previous Rounds of FinanceRound Date Stage Investor (amount)

Companyvaluation

Thousands of Euro Totalamount

1 1/1997 Seed Management (250) 10 250

2Life Sciences Partnering China Europe, 18-19 September 2006

Adamant Biomedical Investments



Country Switzerland

Website www.adamantinvest.comEmail [email protected]

Address Aeschenvorstadt 554051 Basel

Phone +41 2759200Fax +41 2759201

Asset management company

Adamant Biomedical Investments AG is an asset management company focused on the most rapidly growing and profitable segments of the healthcare industry. We currently have more than USD 500 million in assets under management and advisory.

Adamant Biomedical Investments was founded in December 2000 as a joint venture between three former partners of the Bellevue Group and Swiss Life Asset Management, part of the largest life insurance company in Switzerland. The company completed a management buy-out from Swiss Life Asset Management in 2005. In June 2006, it was announced that the third largest, and only AAA-rated, bank in Switzerland, the Zürcher Kantonalbank (ZKB) had acquired a majority stake in Adamant Biomedical Investments. This development not only provides Adamant with the ‘blue-chip’ support of ZKB, but should open up many new avenues for strategic development for Adamant and ZKB.

The focus of Adamant is to invest in the biomedical sector on a global basis. Hence, the company was located, from its foundation, in Basel, the European heart of biomedicine. The core of Adamant’s strategy is fundamental research as well as an active network of scientists, doctors and financial experts around the world. The strategy combines investments in the fields of biotechnology, medical technology and specialty pharmaceuticals. Adamant is a member of the Swiss Association of Asset Managers and is registered by the Eidgenössische Bankenkommission (Swiss regulatory authority). The management team consists of specialists possessing many years of experience in the healthcare industry, in research, development and operational management, and fund management in the biomedical sector.

Adamant is constantly seeking to develop new products for a broader client base, to build the assets under management and to expand the geographical reach of the company.

Technology/Product AdvantageSwiss Life Funds (LUX) - Equity BiomedicalThis mutual fund invests in Mid and Big Cap Biotechs (ca. 60%), Medtech companies (ca. 20 %) and Specialty Pharmaceuticals (ca. 20 %).

Lacuna SICAV - Lacuna Apo BioTech SubfundThe focus of this mutual fund are Small and Midcap Biotech companies (ca. 80%). In addition, the fund invests in Medtech (10%) and Specialty Pharmaceuticals (10%).

Lacuna Sicav – Adamant Asia Pacific HealthThe fund invests in the full value-creation chain of healthcare companies within the Asia-Pacific region: Pharma, Generics, Medtech, Biotech, Hospitals, Service Providers and Diagnostics.

Adamant Emerging Pharma Strategy CertificateThis actively managed certificate invests in listed pharma companies based in the emerging markets, Japan and Australia.

Healthcare - Certificates

Founded 2000


Business Activity

Dr Nicholas Draeger, Investment ManagerEmail: [email protected]: +41 612759200

Presenter


Adamant Biomedical Investments



Adamant Biomedical Investments is seeking partnership for Distribution, Joint Research & Development and Product development.

Partnership Sought

Management TeamDr Nicholas Draeger, Investment Manager

Dr. Nicholas Draeger, Portfolio Manager, Adamant Biomedical Investments

Nicholas Draeger studied Chemical Engineering at the University of Natal in Durban, South Africa, with particular interests in the fields of fluidised bed coal gasification and biochemical processing. He then moved to Cambridge, UK, to research for his PhD in Biochemical Engineering focusing on protein and peptide chemistry and purification. Nicholas also holds an MBA from Warwick Business School, UK.

Nicholas moved to Basel, Switzerland, in 1992 to start his career at Roche, initially as a research scientist in the genetic engineering department focusing on neurodegenerative diseases and HIV diagnostics, and then as a member of the Global Business Development Department of the Pharmaceutical Division, focusing on M&A and licensing. From there, Nicholas moved to be Director of International Business Development at the Italian pharmaceutical company, Recordati.

From 2000, Dr Draeger headed the Biotech Research Team on the sell-side of Credit Agricole Indosuez Cheuvreux and was Scientific Coordinator of the Healthcare Team. He then moved into asset management as a member of the BB Biotech management team, which was responsible for the management of more than CHF 2 billion in assets, at the beginning of 2002. He then joined Adamant Biomedical Investments at the beginning of 2004, as portfolio manager, with particular responsibility for investments in some of the emerging healthcare markets such as India. In parallel, Dr Draeger has carried out health-economic research at the University of Basel, in collaboration with institutes and companies throughout Europe.


Alfama



Country Portugal

Website www.alfama.com.ptEmail

Address Taguspark, nucleo central 2672740-122 Porto Salvo

Phone +351 214240001Fax +351 214240033

Discovery and development of anti-inflammatory drugs

Alfama develops drugs for the treatment of inflammation-related diseases. The company’s immediate goal is to take at least one of its lead compounds to phase I clinical trials directed at a major chronic inflammatory disease such as rheumatoid arthritis. In parallel, Alfama will be pursuing the development of efficient solutions for other large-market therapeutic targets such as myocardial infarction and psoriasis, either fully in-house or through collaborative efforts.The market for anti-arthritis drugs alone will pass the US$10 billion mark by 2008 (source: Nature). Alfama has organized itself in a way that allows it to take the best of its coutry of origin - Portugal - and still be present in the key biotech hubs around the world. Thus Alfama has created a US holding company, with its financial organization complying with US standards and managed by a seasoned American CFO. In parallel, the lead development unit of Alfama will use high-quality CROs from central Europe and is managed out of Geneva by a former top pharma executive. At the same time the bulk of Alfama's science is carried out in Portugal, in association with some of the country's very best scientists and institutes. This way the company is prepared to tap into the very best resources in the World, while creating knowledge, employment and wealth in Portugal.

Technology/Product AdvantageAlfama’s technology is based on the delivery of carbon monoxide (CO) to target tissues through the use of CO-releasing molecules (CORMs). CO is naturally present in our organism, and has been shown to have anti-thrombotic and anti-inflammatory effects. Due to high affinity between CO and hemoglobin, treatments based on external CO should involve drugs that deliver it directly to the target tissues – this is precisely what Alfama’s CORMs do. Importantly, these drugs exert their therapeutic action well below the toxicity levels of CO.Because the therapeutic principle behind CORMs – CO – is established, these molecules do not need to be adapted to a specific target. Thus CORMs can be manipulated in order to have different physiological properties without their basic action being jeopardized. Furthermore, contrary to many drugs, CO is an endogenous molecule which the organism is adapted to. All these facts make CORMs an easy and attractive type of drug to develop for clinical purposes.

Product/Service is currently in R&D

AchievementsFirst patent ever granted on CO releasing molecules for therapyLargest portfolio of CO releasing molecule patent applicationsLargest VC funding round ever for any Portuguese start-upScientific team with over 400 publications in international journals

Founded 2002


Business Activity

Key CustomersPatients, Pharma industry

Key PartnershipsHoffman-La Roche, Serono International, Inst. Molecular Medicine

Key CompetitorsPharma industry, HemoCORM, Sangstat Corp.

Dr Nuno Arantes-Oliveira, Chief Executive OfficerEmail: [email protected]: +351 214240001

Presenter


Alfama



Other informationThis next round of funding should take place when the company is close to obtaining its first IND (investigational new drug) permission. Depending on the results of on-going experiments, that could happen any time between 8 months from now and 30 months from now.

Financing Sought/Investment PlanAlfama is seeking Startup / Early Stage and Expansion / Development financing to the amount of 20 M Euro in exchange for 30% of the company shares.

The capital will be used to take 2-4 lead molecules all the way through phase II clinical trials for large-market inflammatory diseases.

Alfama is seeking partnership for Joint Research & Development, Product development and Manufacturing.

We are primarily looking for partners who will participate in the pre-clinical development of our proprietary compounds, namely by running a selected set of molecules through animal disease models for specific inflammatory or inflammation related diseases such as psoriasis, myocardial infarction, atherosclerosis or stroke.We may also welcome partners who will help us optimize our formulations or delivery systems, and others who will facilitate the organization of our clinical trials.

Partnership Sought

Management TeamDr Nuno Arantes-Oliveira, Chief Executive Officer

Nuno Arantes-Oliveira graduated in Biology from the University of Lisbon, Portugal, in 1997 and immediately afterwards entered the Gulbenkian Doctoral Program in Biology and Medicine. Supported by this program Nuno moved to San Francisco, where he performed research on the genetic bases of aging at the University of California (UCSF) from 1998 to 2002. This work, which was carried out under the supervision of Prof. Cynthia Kenyon, included the achievement of the largest artificial increase in lifespan for any living organism, and led to three publications in the journal Science. In 2002 Nuno successfully defended his doctoral thesis at the University of Lisbon, achieving the highest honors. Back in Lisbon by mid-2002, Nuno became a post-doctoral fellow at the IN+ Center of the Instituto Superior Técnico, where he began studying the socio-economic dynamics of the Portuguese biotechnology sector. In parallel, Nuno became the Chief Executive of ATGC Portugal, a technology-transfer company. Later he co-founded Alfama, Portugal’s first drug development start-up, which, under Nuno’s leadership, has raised the largest round of VC funding ever for a Portuguese company of its type. In recent years Nuno has received several honors and awards from institutions such as the Academia Europaea and the Japanese Government. He started a program for the scientific interaction between Portuguese-speaking countries in Maputo, Mozambique, and is heading or participating in several International R&D initiatives. He has also worked as an advisor to the European Commission, the American Association for the Advancement of Science (AAAS) and the Portuguese Government, among others.

ShareholdersPME Investimentos 22%Werner Haas 17%Carlos Romao 17%Stan Kugell 17%Nuno Arantes-Oliveira 17%STAB Vida SGPS 3%Beta Capital 3%Jorge Sequeira 2%Antonio Jacinto 1%Alfama Foundation 1%


2004 2005 2006 2007 200800 0 2000Turnover

-990-80 -1600 -480EBIT390761 1851 1535Equity

157 15 24Employment


Companyvaluation


1 6/2005 Startup / Early Stage PME Investimentos (3000); Beta Capital (500) 13500 3500


Apeiron Biologics GmbH



Country Austria

Website www.apeiron-biologics.comEmail

Address Brunner Strasse 59/59

A-1230 Vienna

Phone +43 186565779257Fax +43 186565779280

Apeiron Biologics is a biotech company engaged in drug development.

Apeiron's strategy is to generate value by profiling and developing therapeutics up toa first proof of concept in patients (Phase I / II clinical trials). Following successful proof of concept in patients, the aim is to out-licenseprojects to pharmaceutical companies, enabling the initiation of new R&D projects.

Strategic partnerships are being established to combine specific expertise and joinR&D efforts.

Concerning exit strategies, Apeiron is prepared to meet future investors’ preferences.

Technology/Product AdvantageThe primary objective is to develop human Angiotensin Converting Enzyme 2 (ACE2) for treatment of the life-threatening ‘acute respiratory distress syndrome’ ARDS, for which no therapy exists so far. ARDS affects approx. one million patients per year in industrialized countries. �A second project focuses on the identification and development of compounds that act as innovative pain relievers, based on a novel concept to induce the production of endogenous opioids in thepatient, by targeting the key protein controlling this event (DREAM).

Thirdly, Apeiron is engaged in identifying and developing of compounds that shape autoimmunity based on anovel mode of action, targeting a key check-point protein of immune cells (Cbl-b).

All three projects focus on indications for which either no therapy exists or current therapeutic approaches have limitations due to limited efficacy, especially in case of prolonged use, and/or side effects.


AchievementsApeiron has obtained an exclusive, unrestricted license on the worldwide ACE2 patent rights.For DREAM Apeiron has filed a patent application to identify drug candidates based on inhibition kinetics.In the case of Cbl-b a patent application regarding anti-tumor activity in the context of Cbl-b inhibition is in preparation.

Founded 2005


Business Activity

Key CustomersPharmaceutical companies

Key PartnershipsEvotec AG, University of Innsbruck

Key CompetitorsNone

Dr Hans Loibner, Chief Executive OfficerEmail: [email protected]: +43 186565779258

Presenter


Apeiron Biologics GmbH



Other informationIn particular Apeiron seeks a strategic partnership with a Chinese Pharma company for development and outlicensing of ACE2 for the Chinese market.

Financing Sought/Investment PlanApeiron Biologics GmbH is seeking Startup / Early Stage and Expansion / Development financing to the amount of 7 M Euro in exchange for a to be discussed % of the company shares.

Mainly to increase lab capacity by hiring additional experienced personnel and by investing into lab infrastructure.

Apeiron Biologics GmbH is seeking partnership for Joint Research & Development, Manufacturing and Other.

Apeiron Biologics is seeking partnerships for joint research & development, production, and licensing

Partnership Sought

Management TeamDr Hans Loibner, Chief Executive Officer

Has previously founded and successfully developed the Vienna-based biotech company Igeneon (1998-2004, projects in cancer immunotherapy), and was more than 20 years engaged in R&D management with Sandoz/Novartis prior to that.

Mr Lukas Kadawy, Chief Financial OfficerPreviously with IBM.

Dr Manfred Schuster, Chief Scientific OfficerHas previously worked as scientist and project leader with Igeneon, and started his career at the Novartis Research Institute, Vienna.

Ms Liqun Zhang, External Relations and Liaison ManagementMD in Traditional Chinese Medicine (TCM), PhD in Molecular Biology.

ShareholdersJosef Penninger 70%Peter Swetly 20%Hans Loibner 6%Manfred Schuster 4%


2004 2005 2006 2007 20083 10 17 20Employment


Companyvaluation


1 10/2005 Seed Founders (130); Local Investment Agency (500); Grants (Local, Federal, EU) (2100)

2730


Artelis SA



Country Belgium

Website www.artelis.beEmail [email protected]

Address 53, Avenue des Buissonnets1020 Bruxelles

Phone +32 26620292Fax +32 22451223

Development of cell culture bioproprocess for the production of vaccines in single use equipments

ARTELIS is a start-up company located in Brussels, in the R&D site of the SOLVAY chemical and pharmaceutical company.ARTELIS is active in:• The design, development and manufacturing of disposable mixing systems for flexible bags, dedicated to the biopharmaceutical industry, with two main applications:o Pure mixing operationso Conventional agitated bioreactors for mammalian cells in suspension.• The development of biotechnological processes, based on:o ARTELIS’ proprietary technology of high cell density in fixed bed disposable devices.o Conventional cell culture technologies, BUT with the objective of using disposable components.“ARTELIS Devices” is dedicated to the development and manufacturing of disposable devices.“ARTELIS Services” will be a CDO (Contract Development Organization). The CDO will be dedicated to out-contracting of process development, from pre-culture through purification to final filtration of product.

2.1 Missions of Devices• Develop disposable mixers, disposable spargers and disposable sensors, for:o Mixing flexible bags, from 1L to 2000L;o Bioreactors for suspension cell culture, from 25mL to 2000L;o High cell density bioreactors (fixed bed) for cell culture, from 1-5mL to 100L.• Sell disposable mixers and spargers to an industrial partner active in the field of disposable flexible bags, to produce the final products, flexible bags or disposable bioreactors for suspension cell culture.• Life cycle management of mixers, spargers and sensors.

2.2 Missions of CDOThe CDO ARTELIS is the first CDO dedicated to implementation of integrated disposable processes for biotechnological industry. It will offer process development services as follows:• Technical support to customers (end users)• Offer process development services to biopharmaceutical companies, always aiming at maximizing disposable components.• Offer co-development contracts to biopharmaceutical industries related with HCD bioreactors.

Technology/Product Advantage1. Device Business UnitThe core technology of the BU is the use of mixers, classical and High Cell Density bioreactors, fully single use. The components are also single use.This technology presents many advantages:decrease of the operational costs because the sterilisation is confided to the provider;decrease of the investment costs;decrease of the time to market;increase of the reliability;decrease of the contamination risk;decrease of volume;promote the flexibility of a production unit.

2. The CDO Business UnitThe BU are specialised in 2 technologies:the cell culture production for animal cells, mab's,recombined proteins and the combination of single use and HCD bioreactors.Both technologies present the same advantages as the technology used in Devices BU and in addition decrease the volume of a factor 20 to 100.

Product/Service is currently in prototype phase

Founded 2005


Business Activity

Mr Hugues Bultot, Chief Executive OfficerEmail: [email protected]: +32 26620292

Presenter


Artelis SA



Achievements2 patents pending:"Mobilisation mechanism of a liquid substance" and "Single use and High Cell Density bioreactors".

Financing Sought/Investment PlanArtelis SA is seeking Startup / Early Stage and Expansion / Development financing to the amount of 1 M Euro in exchange for 15% of the company shares.

- To pursue the development and to market a coordinated product range.

Key CustomersVaccine & Mab's producers, Biotechs, CMO, Producers of bioreactors

Key PartnershipsBelgian universities, Flexible bag manufacturer

Key CompetitorsDevelopers of devices, Other CDO's

Management TeamMr Hugues Bultot, Chief Executive Officer

-Law degree, Catholic University, Louvain-La-Neuve, Belgium, 1989.-Certificate of comparative criminology,Universidad del Pais Vasco, Spain, 1989.-International Management Program,CEDEP/INSEAD, 1997/1998.-DES in management, Sovay Business School,Belgium, 1992.-DES in tax management, ICHEC,Belgium, 1998.MR Bultot is "high tech"entrepreneur with a broad entrepreneurial and operational management experience in emerging companies. During his 10 years in the private equity sector, he has been responsible as CEO,investment manager,COO,advisor to academic institutions and founder of university spin-offs. The strongh results he achieved are due to his technical background,, his stratégic vision and his ability to execute in uncertainty.

Mr José Castillo, Director He is also the cofounder-Chemical Engineering degree, University of Brussels, Belgium, 1992.-PhD in Applied Sciences(organic chemistry), University of Belgium, 1998.-One year cycle at the Solvay Business School, Belgium, Award of Best Business Plan, 1998.Mr Castillo is a"great inventor" with a broad R&D experience in university environements and an operational successful experience as Head of Department in the Industrialization Department of a large company working in the field of Biotechnology. He is well-known for his invention and innovation abilities and his easy way to manage people throughout new projects steps.

Mr Nicolas Havelange, Manager-Master in Chemical Engineering,Ecole polytechnique de l’Université Libre de Bruxelles,Belgium,1994.-Solvay S.A. / ULB Industrial and analytical chemistry department,research engineer, Brussels,1997/1998.-Master in Molecular Biology and biotechnology,ULB,Belgium,1998.-SmithKline Beecham Biologicals (now GSKBio), management trainee,Rixensart (Belgium), 1998.-Réalco S.A./ UCL Unité de Génie Biologique, research engineer, in Louvain-la-Neuve (Belgium),1999.-Dow Corning S.A., Production Planner, in Seneffe (Belgium),2000.-Henogen S.A., Process development director and then Business develoment in Gosselies and Seneffe (Belgium),2001.

ShareholdersHugues Bultot 50%José Castillo 50%


2004 2005 2006 2007 2008660 3279Turnover

200 200Equity2 16 20 20Employment


Companyvaluation


1 7/2006 Startup / Early Stage Big suppliers of Biotech industry (1000); Major players of the vaccine industry (1000)

5000


AstraZeneca



Country China

WebsiteEmail [email protected]

Address 43F Citic Square, 1168 Nanjing West Road200041 Shanghai

PhoneFax

AstraZeneca is a leading multinational pharmaceutical company

AstraZeneca is a leading multinational pharmaceutical company. AstraZeneca China has its headquarters in Shanghai, with branch offices in more than 20 cities across mainland China. A world-class manufacturing site in Wuxi, Jiang Su Province was inaugurated in 2001. About 80% of the products it sells in China are manufactured in Wuxi.

Since AstraZeneca came to China in 1993, we now have more than 2000 employees involved in the manufacturing, sales, marketing and clinical research of new products. Following our concept of "in China, for China," we developed four key strategies: develop innovative products, strengthenpartnerships with local research institutions, develop local talent, and practice good corporate citizenship. Since 2002, AstraZeneca has sustaineda healthy and rapid development in China. The company now leads other multinational companies in prescription drugs sales and international multi-center clinical trials.

The mission of AstraZeneca China is to develop, supply and market highly innovative medicines of superior quality in our prioritized therapeutic areas in China. We are determined to conduct our business responsibly, strengthen our long-term commitment to China and become a partner of choice.

AstraZeneca is committed to being a good corporate citizen and aspires to be the partner of choice for China''s medical community. In an effort to improve R&D capabilities of local partners, AstraZeneca has collaborated closely with distinguished academic and research institutions. The companyalso allocates significant resources to educating Chinese medical professionals on latest clinical findings and best international practices.

Founded


Business Activity

Ms Jie D''Elia, Director Business DevelomentEmail: [email protected]: +86 2152564555

Presenter

Management TeamMs Jie D''Elia, Director Business Develoment

Jie joined AstraZeneca China in March this year to head the businessdevelopment department. Prior to AstraZeneca, Jie is a Senior manager at Nastech Pharmaceutical, a biotech company based in Seattle, Washington, USA. Jie spent her early career as a management consultant at the Boston Consulting Group, helping Fortunate 500 companies on strategic and operational issues. Jie holds a Ph.D. in Pharmacy from the University of Texas at Austin and an MBA from Columbia Univeristy.


AstraZeneca



AstraZeneca is the leading ethical prescription MNC in China and has been growing strongly at over 30% for the last three years. This is based on field force and marketing investments, strong distributor networks, and strong national and provincial government affairs support driving rapid market access and listing. Today we are also pleased to be the leading MNC in terms of clinical development and have excellent relations with investigators as well as CDE and SFDA. This is reflected in good dialogues regarding clinical programs and rapid CTP approvals. As part of our long-term strategic plan, we are committed to seeking partnership opportunities which can provide AstraZeneca with access to high value, high quality products in the China market. We believe that we could add value to the partnership by leveraging our strong sales, marketing, R&D, and commercial operations capabilities to fully exploit the market potential of the licensed products.

Partnership Sought


Astrom Research International



Country Sweden

Website www.astromresearch.comEmail

Address Astrom Research InternationalIdeon Science ParkSweden

SE - 223 70 Lund

Phone +46 462862630Fax +46 462862634

CRO/SMO focusing on China

Astrom Research International (ARI) provides international and domestic pharmaceutical, biotech, and medical device companies with clinical trials services in China. ARI works through a network of major hospitals across China and offer clients the full scope of clinical trial services.

Technology/Product Advantage- Strong network of partner hospitals- Project Management on site or in Europe


AchievementsPlease contact us for more information

Founded 2004


Business Activity

Key CustomersPharma, Biotech, Medical device

Key PartnershipsMajor Chinese hospitals

Key CompetitorsInternational CROs, Domestic CROs

Dr Stefan Astrom, Chief Executive OfficerEmail: [email protected]: +46 462862630

Presenter


Astrom Research International



Financing Sought/Investment PlanAstrom Research International is seeking Startup / Early Stage financing to the amount of 0.7 M Euro in exchange for a to be discussed % of the company shares.

We like to meet EU companies in the phase of establishing in China or who wants to document pharma / biotech products in China phase I - IV clinical trials.

Partnership Sought

ShareholdersFounders 100%


Companyvaluation


1 1/2004 Seed Founders


Bayer BioScience China



Country China

Website http://www.bayercropscience.com

EmailAddress 34/F Jing Guang Center,

Hu Jia Lou, Chaoyang District100020 Beijing

Phone +86 861065973181Fax

BioScience is the seed and trait business of Bayer AG, German pharmaceutical and chemical Company.

BioScience is the seed and trait business of the Bayer Company and is one of six Business Operations Units in Bayer CropScience.Using the tools of modern plant breeding, including plant biotechnology, our seeds become a vehicle for delivering improved crop quality, increased yields and innovative plant-based solutions to meet the increasing need for renewable resources.Research and DevelopmentOur main research competence centers are in Gent (Belgium), Potsdam (Germany) and Lyon (France). We also have many development sites and research collaborations around the world. The research and development budget for plant biotechnology and breeding activities for 2005 was around 90Mio Euro. We are investigating a range of topics, including improving the agronomic performance of crops in terms of enhanced herbicide tolerance, disease and insect resistance and yield and quality enhancements.

Technology/Product AdvantageRice is one of the four strategic crops in the BioScience seed and trait business, together with canola, cotton and vegetables.BioScience rice activities focus on the development of high-yielding hybrid rice seeds.Our rice business is building on our leadership position in hybrid rice in India to become a global leader in the development, production and sale of hybrid rice seed. BioScience activities with hybrid rice in China are planned to start in 2007 through a joint-venture.Our global umbrella brand for hybrid rice seeds is Arize ® - a range of products adapted to various agronomic climatic conditions and consumer preferences combining high yield, excellent grain, cooking and taste qualities and high quality seed.


Achievements

Founded 2003


Business Activity

BioScience is already present in China with its Nunhems vegetable seeds business. BioScience intends to develop in the near future its agricultural crop seed activities in China (development, breeding, production and sales of seeds). This will start through joint-venture in 2007 with hybrid rice, and will be followed with canola and cotton. Plant biotech research activities are also considered in this frame, for instance on insect-tolerant rice (Bt-rice).These various upcoming BioScience seed activities should lead to partnering opportunities in China.

Partnership Sought

Mr Philippe Medeau, General Manager BioScience ChinaEmail: [email protected]

Presenter

Management TeamMr Philippe Medeau, General Manager BioScience China

Educational background in Agronomy and Business Administration.Working for Bayer Company since 1986, in different countries.Last responsibility in Bangladesh, running Bayer CropScience agrochemical business, and initiating BioScience first trials with hybrid rice.Appointed in July 2006 to create and develop the Bayer BioScience activities in China.


BioDetection Systems bv



Country Netherlands

Website www.bds.nlEmail [email protected]

Address Kruislaan 4061098 SM Amsterdam

Phone +31 204350759Fax +31 204350757

Life Science Technologies for food/feed/medicin/ chemistry/pharmacy testing eg dioxins/hormones

Life Science CompaniesScience InstitutesWorldtrade Companies - Import from feed/food to EuropeWaste Recycling Steelmakers such as Baosteel Public Health Institutes such as CDC Environmnetal Protection Agency (EPA) Several Universities doing Environmental Protection of Feed/Food Testing Global Feed/Food companies such as Nutreco, Unilever etc Global Chemical Companies such as Bayer or BASF Remediation and Construction Companies such as URS Environmental engineersPharmaceutical Companies such as Schering Distributors of Analytical technologies such as BCT

Activities:Service AnalysisLicensingTrainingConsulting

Technology/Product AdvantageCALUX - cheaper, faster, high quality Screening for dioxins and hormonesMore than 30 laboratories in more than 20 countries are userPortfolio of 8 CALUX bioassay systems for dioxins, endocrine disrupters, sport doping, Asthma spray, water testing, sediment/soil health or flame retardants

Product/Service is currently shipping/selling

Founded 2001


Business Activity

Key CustomersGlobal PLayer feed food, Chemical Companies, Pharmaceutical Companies, Public Health Institutes, Environmental Protection , R&D Institues

Key PartnershipsFree University Amsterdam, RIKILT

Key CompetitorsSGS, Eurofins, Alta, Biosense

Dr Peter Behnisch, DirectorEmail: [email protected]: +31 204350759

Presenter


BioDetection Systems bv



AchievementsTechnology is trademarked and the Global MarketleaderMore than 30 licenses worldwideAccepted by EU guidelinesService Laboratory ISO 17025 accreditedMore than 200 projects and publications used

BioDetection Systems bv is seeking partnership for Distribution, Joint Research & Development and Sales.

Biotech DistributorsFeed and Food Import Institutes Life Science CompaniesBiotech Research InstitutesService Laboratories such as SGS or EurofinsWorldtrade Companies - Import from feed/food to EuropeWaste Recycling Companies such as RWE, Remondis Steelmakers such as Baosteel Public Health Institutes such as CDC Environmnetal Protection Agency (EPA) Several Universities doing Environmental Protection or Feed/Food Testing Global Feed/Food companies such as Nutreco, Unilever etc Global Chemical Companies such as Bayer, Dow or BASF Remediation and Construction Companies such as URS Environmental engineersPharmaceutical Companies such as Schering Distributors of Analytical technologies such as BCT

Partnership Sought

Management TeamDr Peter Behnisch, Director

Director, BioDetection Systems, Amsterdam, The Netherlands: Responsible for Global Development

2004-2006: Laboratory Manager, Eurofins GfA, Münster/Hamburg, Germany. Eurofins International Management Team2003-2004: Life Science Manager Germany, SGS NATEC GmbH, Hamburg, Germany 2002-2003: Environmental Service Manager Germany, SGS Fresenius, Wismar/Hamburg, Germany1998-2002: Teamleader, Life Science Kaneka Corp., Kobe, Japan1998: Postdoc, at Prof. Kevin Jones, Lancaster University, England1997: Chemical Safety Assistent at Kärcher Ltd., Oxford, England

ShareholdersFree University of Amsterdam 50%Prof. Bram Brouwer 50%


2004 2005 2006 2007 200820001500 2500 3000Turnover10020 200 300EBIT2015Employment


BioGeneriX AG



Country Germany

Website www.biogenerix.comEmail [email protected]

Address High Tech Park NeckarauJanderstr. 368199 Mannheim

Phone +49 621875560Fax +49 6218755633

Generic pharmaceuticals

BioGeneriX AG is a spin-off of ratiopharm GmbH, Germany’s market leader in generic pharmaceuticals. We focus on the emerging demand for generic versions of biotech drugs. BioGeneriX covers all steps in product development from cloning and cell banking to process development, clinical and pharmaceutical development until EU registration. We are backed by a laboratory function, dedicated to cell culture, process development and protein chemistry and by patent and business development units.

Technology/Product AdvantageBioGeneriX AG is ready to provide partners with advanced biotech generic developments. Due to the regulatory requirements being substantially higher for follow-on-biologics than for chemical generics, risk and cost sharing by jointly developing follow-on-biologics seems most appropriate.The development of our products is always geared to functional added value through the benefits for patients, healthcare systems, doctors and sales partners.

BioGeneriX will improve existing therapies and provide high-quality medication to the community at a fair price.

Instead of a virtual management, we work through our own specialists. The cornerstones of our organisation are project management, biotech know-how, expertise in legal and patent affairs, business intelligence and the management of alliances within the BioGeneriX AG.

Founded


Business Activity

Mr Elmar Schäefer, Chief Executive OfficerEmail: [email protected]

Presenter


BioGeneriX AG



BioGeneriX AG looks forward to enter into strategic alliances, as well as partnerships for selected products or single development steps. Partnership with BioGeneriX may open co-operation with ratiopharm, Europe’s most successful distributor of generic pharmaceutical products.

Partnership Sought

Management TeamMr Elmar Schäefer, Chief Executive Officer

Elmar Schäfer is Chief Executive Officer of BioGeneriX AG, Mannheim, Germany. BioGeneriX is an internationally operating company, developing and licensing generic biopharmaceuticals to be sold by distribution partners.

Prior to joining BioGeneriX in April 2001, Elmar Schäfer was Director of Business Development at Glaxo Wellcome, Hamburg, Germany (1997-March 2001), Head of Legal Affairs and Cooperations at Glaxo Wellcome, Hamburg, Germany (1995-1997), and Legal Advisor at Wellcome, Hanover, Germany (1992-1995).

Elmar Schäfer was previously an Attorney at Law in private practice, specialized in Business and Corporate Law (1989-1992). He did his legal traineeship in the Düsseldorf area (1986-1989), after receiving his law degree from Westfälische-Wilhelms-Universität, Münster, Germany in 1986.

Dr. Klaus Maleck (CFO), formerly McKinsey

Dr. Thomas Brennecke (Head of Business Development

Dr. Erich Kohler (Head of Development), formerly Boehringer Mannheim

Dr. Axel Angermann (Head of Product Supply Management,) formerly Biotest

Dr. Walter Hinderer (Head of Patent Affairs), formerly Biotest.


Cerenis Therapeutics sa



Country France

Website www.cerenis.comEmail [email protected]

Address BP 87519, Rue de la Découverte31675 Labege cedex

Phone +33 562249706Fax +33 562190417

A pharmaceutical company focused on the discovery and development

Cerenis Therapeutics is a privately-held pharmaceutical company working to develop novel and innovative HDL based therapies with a multiple product franchise for the treatment of cardiovascular disease. Cerenis has identified and initiated a range of early-stage development initiatives including synthetic and small molecule HDL products that are positioned to represent significant advances in HDL therapy and major commercial opportunities for the company. Cerenis is led by an international management team of seasoned experts in HDL research and product development. Their combined clinical, business, regulatory and manufacturing experience will advance the company''s research programswith the goal of expediting novel HDL therapies to market.

In July 2005, Cerenis completed a $30.5 (€ 25 million) million Series A financing involving an international syndicate of leading life science and biotechnology investors. The company is now well positioned to execute research and development programs to bring multiple product candidates tothe point of initial proof of concept.

The expanding interest in HDL therapy and Cerenis''s innovative approachesfurther position the company to pursue a number of options in financing,research alliances, in-licensing, corporate partnerships and mergers & acquisitions in the years ahead.

Founded 2005


Business Activity

Research alliances, in-licensing, and corporate partnerships in the cardiovascualr and metabolic diseases area.

Partnership Sought

Dr Larry Zhu, Director Business DevelopmentEmail: [email protected]: +33 562249706

Presenter

Management TeamDr Jean-Louis Dasseux, Chief Executive Officer

Dr. Dasseux is the inventor of a high capacity reverse lipid transport peptide (ETC-642) as well as a series of small molecule products that elevate HDL. These programs represented key elements of Esperion's scientific programs, which led to the acquisition of the company by Pfizer for $1.3 billion in 2004. Dr. Dasseux was vice president of chemistry and technology and chair of the ETC-642 development team at Esperion Therapeutics, and was previously the director of research for Fournier where he established and managed their research center in Heidelberg, Germany.

Dr Larry Zhu, Director Business DevelopmentDr. Zhu was the head of Licensing & Development for Esperion Therapeutics,a division of Pfizer, and member of the Pfizer Global CardiovascularLicensing Leadership Team until October 2005. Prior to that, he was thesenior manager of business development for Esperion Therapeutics, Inc.,and participated in all partnering activities that led to the acquisitionof Esperion by Pfizer. Dr. Zhu was also the project chair for the ETC-216(ApoA-IMilano) Development Team at Esperion that completed the ETC-216-002trial (Phase 2 in US).


Degussa AG



Country Germany

Website www.degussa.comEmail [email protected]

Address Rodenbacher Chaussee 463457 Hanau-Wolfgang

Phone +49 6181592072Fax +49 6181593930

Multinational corporation consistently aligned to high-margin specialty chemistry.

Degussa is a multinational corporation consistently aligned to high-earning specialty chemistry, ranking no.1 worldwide in this area. Our innovative products and system solutions make valuable contibution to our customers' success. In 85% of its businesses Degussa, having 70 main production sites and more than 40 research sites, holds 1-3 positions. Around 75% of its sales are generated abroad. Degussa have employees on all continents. Main areas of future growth are seento be in China and in Eastern European countries.

Technology/Product Advantage- Acrylic glass for construction industry,aviation + aerospace appl.- Amino acids for feed, food + pharma applications- Amphoteric surfactants for personal care. - Colorants for decorative and industrial applications- Fumed and preciptated silicas for rubbers, paints, coatings, plastics, cosmetics, pharmaceuticals, electronics, insulation- Heterogeneous, homogeneous and bio-catalysts for fine chemicals- Peroxocompounds as bleaching agents and initiators- Polyamide-12 for high performance polymer applications- Polyester resins for can and coil coating- Exclusive synthesis of fine chemicals for pharma and agro appl.- Superabsorbants for diapers and hygiene products- Carbon black for tires, rubber goods, pigments- Hydrogen peroxide for bleaching of pulp + paper- Isononanol for plasticizers - MMA for dispersions, lacquers, additives, adhesives, optic. lenses- PMMA engineering polymers for automotive, electronics, medicals- Sodium cyanide for gold extraction


Founded 2001


Business Activity

Key CustomersAutomotive Industry, Pharma and Agro Industry, Feed+Polymer Industry, Cosmetic + Care Industry , PolymeElectronic Industry, Coatings+Colorants Ind.

Key Partnershipswith innovative customers, universities, tech companies, other R&D institutions, funding agencies, start up companies

Key Competitorsother spec. chem. comp.

Dr Karlheinz Drauz, Vice President Corporate Innovation ManagementEmail: [email protected]: +49 6181592072

Presenter


Degussa AG



AchievementsFor the Year 2005:-Degussa established 8 new companies in China-Degussa is the first global chemical company operating to obtain import and distribution permits-Cooperation with Jilin University started on development and production of High-temperature polymers-investments of about €100 million in China-ca 400 new patents and patent applications

Financing Sought/Investment PlanDegussa AG is seeking Expansion / Development financing to the amount of 11000 M Euro in exchange for 15% of the company shares.

For strengthen existing market positions in China as well as for new technology / product acquisitions.

Management TeamDr Karlheinz Drauz, Vice President Corporate Innovation Management

1970 – 1978 Studying chemistry at University of Stuttgart, Dr. rer. nat. in Organic Chemistry1980 Joining Degussa AG in R+D (amino acids, H2O2)1984 Supervisor (Agro and new product developm.)1985 Research Manager in the area ofAmino Acids and Peptidessince 1988 Lecturer at University of Würzburg1992 Honorary Professor1994 Vice President, Head of R+D Fine Chemicals of Degussa (old) incl. Production at Wolfgang1999 Vice President, Head of R+D Fine Chemicals of Degussa-Hüls 2001 same for Degussa (new)2002 Vice President, Head of Technology and R&D Management of Degussa Fine Chemicals2003 Vice President and Chief Technology Officer of Business Unit Exclusive Synthesis and Catalystssince July 2005 Vice President Corporate Innovation Management International Scientific RelationsScientific contributions 249 patents and scientific papers, 152 lectures and postersSpecial research interests·amino acid and peptide chemistry·bio and chemo catalysis·asymmetric synthesis·process development and intensification

ShareholdersRAG 100%


2004 2005 2006 2007 20081180000Turnover940000EBIT

4186000Equity45553Employment


Companyvaluation


1 12/2005 Expansion / Development Degussa (100000)


DR MYKO SAN - HEALTH FROM MUSHROOMS ltd Ltd.



Country Croatia

Website www.zdravljeizgljiva.hrEmail [email protected]

Address Vijenac Frane Gotovca 810010 Zagreb

Phone +385 12920290Fax +385 14660095

Manufacturing of health preparation from medicinal mushrooms.

Manufacturing of products from medicinal mushrooms (based on own recipes) and selling them to final users directly.

Technology/Product AdvantageFirst European company specialized for manufacturing of medicinal mushroom products, with 10 standard products based on own recipes, antitumour mushroom extracts partly scientifically verified and more and more popular in use in Croatia.


Achievements- Some patients with complete tumour regression (including children) and many patients with significant tumour regression, hepatitis C regression, effective lipids and blood sugar control, etc.- Share in copyright on scientific article regarding research of antitumour effects of mushroom preparations in International Journal of Medicinal Mushrooms, New York, Nr. 2/2004. - Proprietory share in the future results of scientific testing of antitumour effects of 25-30 mushroom species, in partnership with Croatian leading scientific Rugjer Boskovic Institute, under the sponsorship of Croatian Ministry of Science and Education.

Financing Sought/Investment PlanDR MYKO SAN - HEALTH FROM MUSHROOMS ltd Ltd. is seeking Expansion / Development and Startup / Early Stage financing to the amount of 5 M Euro in exchange for a to be discussed % of the company shares.

At the moment we don't seek any financing.In the near future (in the year 2007.) we will start to seek for a new finance sources - for the purposes mentioned on the list in the answer below.However, we have not calculated them precisely at the moment.

Founded 1990


Business Activity

Key Customerscancer patients/ families, cardiovascular patients, diabetics, viral infected patients

Key Partnershipssome Croatian media, some scientific instituts

Key Competitorspharmaceutical companies, some herbals sellers, spiritual/magic

Dr Ivan Jakopovich, General ManagerEmail: [email protected]: +385 12920290

Presenter

Management TeamDr Ivan Jakopovich, General Manager

1977-1990 Employed (as a political scientist) in Union federation of Croatia1990- Cofounder and general manager in DR MYKO SAN - HEALTH FROM MUSHROOMS Ltd

ShareholdersManagement team-founders 100%


DR MYKO SAN - HEALTH FROM MUSHROOMS ltd Ltd.



Other informationThe list of our priorities: (1) better visibility in the public opinion and on the market, (2) more clients in Croatia and other countries, (3) additional finance for the growth and modernization of our production unit... (4) ...and sales and marketing network, (5) solid partnership(s) for expanding our production and sales through the European Union.

One of fundaments of our company DR MYKO SAN - HEALTH FROM MUSHROOMS is in millenial experiences of Traditional Chinese Medicine, and we already have the cooperation with some Chinese companies.Therefore we will be very glad for the chance to deepen these experiences and seek for new potential Chinese partners in the meeting of such a high level.

Our colaboration with some Chinese companies is now in an initial stage of supply with several organically grown mushroom species as a raw materials for our medicinal mushroom extracts.This colaboration should be widened and promoted with new reliable suppliers of more organically-grown and wild-collected mushroom species, who are capable to guarantee for needed bacteriological and chemical purity.

The next higher level of our development will also include the industrial production of certain mushroom species mycelium for the extraction of medicinal compounds, including a selection of the most efficient medicinal mushroom strains.The Chinese companies with skilled and experienced professional staff in this field could be the welcomed partners.

The main goal of our further development is the expanding on the EU market and the positioning as the main supplier with our highly effective medicinal mushroom preparations against cancer, viral infections, cardiovascular and neurodegenerative diseases.It requires (1) to build a technically advanced industrial factory with sufficient capacity for start and expanding, and (2) to establish an efficient marketing and sales net, which is necessary for the placement of medicinal mushroom preparations on the EU market.Therefore we wish to find a potential Chinese partners for this large enterprise – there is a number of possibilities for financial, technical and commercial cooperation in this field (as the colaboration, partnership and/or joint venture).

In the conclusion I wish to point out that our company will start seeking for a strategic partner(s) for the expansion into the EU market in the next year, that we definitely will need a new capital and high quality business cooperation for the technical modernisation and financing and organizing of marketing activities in EU market - but we are not interested for strictly traditional investors who are interested only for the maximal returning rate.We are interested only for such partners who have sufficient patience and passion for seeking and developing really new products and trends, to reveal and learn a new things and to share the risks and (extra)profits from real pioniering enterprises.

Partnership Sought


2004 2005 2006 2007 2008225170Turnover

98Employment


Companyvaluation


1 1/1996 Seed Founders (1); Sindi ltd (loan) (2)2 1/2000 Startup / Early Stage DR MYKO SAN (self-financing) (10)3 1/2005 Expansion / Development DR MYKO SAN (self-financing) (70)


DSM Nutritional Products



Country Singapore

Website www.dsmnutritionalproducts.com

EmailAddress 78 Shenton Way #21-01

079120 Singapore

Phone +65 63256260Fax +65 62201976

DSM Nutritional Products develops, manufactures, & distributes vitamins & functional ingredients

DSM Nutritional Products, formerly known as Vitamins & Fine Chemicals Division of F. Hoffman-La Roche, maintain its tradition as a pioneer in the discovery of new products, new formulations and attractive applications for all industry segments. We have our own research centers, production facilities and a world-wide sales and distribution network. Building on our long tradition of leadership in this industry, we are committed to continuously providing outstanding products and services for human well-being.

Technology/Product AdvantageAll of the products of DSM Nutritional Products are backed with strong science for efficacy and safety and passed rigorous quality checks. Regulatory compliance of our products are also assured by a team of Regulatory experts.

Product/Services include water and lipid soluble vitamins, carotenoids, and functional ingredients such as omega-3 fatty acids, epigallocathechin gallate, and others. The majority of our ingredients are trademarked for further finished product differentiation.


Founded 1902


Business Activity

Key CustomersNestle, Kelloggs, Wyeth, Coca Cola Company, Pepsi Co, Unilever

Key PartnershipsKemin, CreAgri, Hyben Vital, Crina

Key CompetitorsBASF, Cognis, Chr. Hansen, LycoRed, Cargill, ADM

Ms Veronita Rusli, Manager Innovation PartnershipsEmail: [email protected]: +65 63256260

Presenter


DSM Nutritional Products



AchievementsDSM patent activity is one of the highest in Europe. We continuously apply for patents and defend them as necessary.

Technical expertise in product concepts and development makes our ingredients very versatile for applications in a wide range of food, beverage, and nutrition supplements.

ShareholdersDSM 100%


2004 2005 2006 2007 200882000007800000Turnover

2100022000Employment


Eamerge International Business



Country Netherlands

Website www.eamerge.comEmail

Address Burg. Reigerstraat 893581 KP Utrecht

Phone +31 302285221Fax +31 302285227

Pharma service organisation

Eamerge International Business focus is on bridging Europa - Far and Middle East. Eamerge IB is a partner organisation of Bactimm, Farmalyse and Interdos Pharma.

The company name Eamerge is build up by words and regions Europe, Africa, Middle East, Merge (supply and demand), Emerging countries.

Our focus is on developing our contract services in the Far East and Middle East. We have three service channels with various service opportunities.

First service channel is "Documentation management" that is related to DMF reviews, support, validation studies, regulatory compliance and registration support.

The second service channel is called "Operation management". Bactimm and Farmalyse are the accredited organisations by the Dutch Ministry of health. We focus on QC, QA and batch release analyses. More precisely: non-EU producing pharmaceutical companies (China) are obliged to have their medicines analyzed on EU territory for export purposes by accredited organisation. The third service channel is "Supply management". In this channel we focus on Back and front office services in relation to distribution. This also involves logistics, warehousing, distribution and sales service support of (mainly) generics.

With our service scope we want to be your major buisness partner.

Technology/Product AdvantageOne business partner in Pharma service to enter Europe or for outsourcing the pharma analyses and Regulatory service.

Founded


Business Activity

Mr Ardie van Lankveld, General Manager Eamerge International BusinessEmail: [email protected]: +31 302285221

Presenter


Eamerge International Business



Production, Research

Partnership Sought

Management TeamMr Ardie van Lankveld, General Manager Eamerge International Business

Started to study Food technology followed by Food and Marketing. Finished my MBA on the NIMBAS Bradford University.

Started my carrier in the Flavour and Fragrance industry in 1994 and became Commercial business manager responsible for Flavour sales team Middle East of International Flavours and Fragrances. In the period we developed the market very successful in Pharma and food flavours.

At this moment I am the managing director of Eamerge International Business. Eamerge is the partner organisation of Bactimm Farmalyse and Interdos Pharma. Together we developed a successful service concept for the Pharma industry in the Far and Middle East.


Ecocoal, s.r.o.



Country Czech Republic

Website www.ecocoal.czEmail [email protected]

Address Vršovců 1048/2970900 Ostrava

Phone +420 602781122Fax +420 596616600

Research, development, production and aplication of environmental technology

Remediation of contaminated sites, Waste treatment and recycling, Decontamination of soil and groundwater, Biotechnology – Biofilters, Mechanical separators, Production of building materials, products and raw materials for their production, Technology for processing of waste from metallurgical processes, mining, power industry, pulp industry as raw materials for secondary utilization, Consulting and engineering services,

Technology/Product AdvantageTechnology of reduction odour and polution (air polution control)Technology for processing of waste from metallurgical processes, mining, power industry, pulp industry as raw materials for secondary utilization


Achievementsmimimg industry, metalurgical industry (spec. in person), pulp industry, power industry

Founded 1995


Business Activity

Key Customersmetalurgical industrie, pulp industir, mining industrie

Key Partnershipsaccredited laboratory, R&E centter, Technical Universities

Key Competitorslandfill, unecological operation

Mr Marek Dlabaja, Marketing & Sales Director envirinmental technologyEmail: [email protected]: +420 602781122

Presenter

Management TeamMr Marek Dlabaja, Marketing & Sales Director envirinmental technology

My basic qualification is in Economics (Finance) and in edition I have background of education in environmental technologies supported by 9yrs of experience in the field of environmental technologies principally applied to heavy industrial applications working for Ecocoal s.r.o. During this time I have had a chance to work with the company on a variety of projects spanning from ecologisation of coking towers to reclamation of brownfield environmental sites using technolgies for decontamination of soil and groundwaters. My core expertise lies within technology for minimisation and utilisation of waste for metallurgical, mining, power and pulp processing companies. Of late I am focusing on air pollution control and bio-technological solutions for deodourisation, bio-filters. The scope of my present work requires me to deal with issues concerning sales, research and implementation of aforesaid technologies.”


Ecocoal, s.r.o.



Financing Sought/Investment PlanEcocoal, s.r.o. is seeking Seed and Startup / Early Stage financing to the amount of 1 M Euro in exchange for a to be discussed % of the company shares.

For development and production of technology for minimalization of polution in the industrial waste (neutralization, solidifikation, reaction between special compounds etc.) Air polution control - biofilter-system

Ecocoal, s.r.o. is seeking partnership for Joint Research & Development, Manufacturing and Sales.

Our company is interested in establishing cooperation and utilizing our experiences for solving the environmental problems of such heavy industries. We would like to find partners from industrial companies that can discuss their problems. Owing to our very strong R&D capacity and extensive experience we can propose solutions which are backed by references and empirical results from our previously handled sites.

Partnership Sought

Shareholdersnone


Companyvaluation


1 4/2004 Expansion / Development Ecocoal, s.r.o. (1000)


F2G Limited



Country United Kingdom

Website www.f2g.comEmail [email protected]

Address PO Box 1, Lankro WayEcclesManchester M30 OBH

Phone +44 1617851270Fax +44 1617851273

Discovery and development of improved treatments for systemic fungal infections

F2G is addressing the growing antifungal market in both the tertiary and primary care sectors. The total market value for anti-fungal drugs is approximately $5.2bn per annum, and has grown consistently over the past 10 years. The USA represents approximately 50% of this market. The increases are largely due to rising numbers of immune suppressed patients at risk from fungal infections, and could further increase by better diagnostics.

F2G has been established on a very flexible business model maximising expenditures on science and able to add resources to accelerate progress if circumstances warrant.

Key points:·Flexible business and operating model·Utilise the patented MycoBank® technology to identify Targets·Implement whole cell screening against a range of clinically relevant fungal and bacterial pathogens·Progress compounds through LI, LO, pre-clinical and through to phase II·Build value through developing an antifungal compound pipeline·Position the Company for a potential trade sale or merger

Technology/Product AdvantageF2G’s patented MycoBank® technology gives the Company a competitive advantage. F2G has a significantly higher probability of discovering the next class of antifungal compound by utilising the MycoBank® to identify genetic pathways and essential genes that are necessary in order to identify compounds which meet the market needs. In addition, F2G’s large and diverse compound collection allows the Company to screen for activity and design compounds that are profiled against the market needs. Our compounds are designed to meet the whole range of the antifungal market rather than a limited spectrum, therefore, providing greater returns than

compounds currently reaching the market or compounds presently in development.


AchievementsSuccessfully taking compounds through the LI process and one compound into LODevelopment of disease models for drug testingOur patent portfolio includes:

Mutant Bank AU4853001 A; CA2403317 A1; EP1272610 A1; GB0008748D D0; JP2003530099T T; NO20024898 A; NO20024898D D0; NZ521451; US2003129733 A1; WO0177295 A1 (filed 11-4-2000)

Founded 1998


Business Activity

Key CustomersPharma companies, Agri-science companies

Key PartnershipsUniversity of Manchester, Institut Pasteur Paris, University of Sheffield, EURESFUN Consortium

Key CompetitorsPharma Companies

Mr Shane M Kelly, Chief Executive OfficerEmail: [email protected]: +44 1617851271

Presenter


F2G Limited



2031 Oxidoreductase GB0403746.1; GB0424080.0; PCT/GB2005/000623 (filed 19-2-2004)Transposon mutagenesis GB404433.5; PCT/GB2005/00743 (filed 27-2-2004)Fungal signalling and metabolic enzymes GB426390.1 (filed 1-12-2004)Promoter system GB602435 (filed 7 –2- 2006)Antifungal agents GB510190.2 (filed 18-5-2005)

Financing Sought/Investment PlanF2G Limited is seeking Mezzanine and Pre-IPO Financing financing to the amount of 7 M Euro in exchange for a to be discussed % of the company shares.

To expedite progress on lead compounds and extend financial runway.

Management TeamMr Shane M Kelly, Chief Executive Officer

Shane has extensive experience building, financing, and managing early and mid size growth companies. During the past 10 years he has arranged sources and terms for over $90,000,000 in equity (and subordinated debt) funds, as well as over $50,000,000 in senior debt transactions. He has participated on a senior level with rapidly growing biotechnology and traditional businesses in financing strategy, growth strategy and mergers and acquisitions. Shane has previously been founding Chief Executive of two venture-backed firms in the United States.

Dr Mike Birch, Vice President OperationsMike is one of the original members of the F2G scientific staff. He is responsible for the initial development of F2G’s core MycoBank® technology and has over fifteen years of research experience in commercial and academic laboratories, predominantly working on Aspergillus and pathogenic fungi. Over this period he has developed a wide network of contacts in the fungal research community.

Dr Lloyd Payne, Vice President Research & DevelopmentLloyd is an experienced medicinal chemist with a proven track record in an early stage drug development. As senior scientist at Millennium Pharmaceuticals, he was responsible for several preclinical drug discovery programs and led multidisciplinary project teams based in the UK and US. During this time Lloyd developed expertise in the identification and optimisation of small molecule NCE’s and developed an extensive network of contacts within the biotechnology and pharmaceutical sectors.

ShareholdersBankInvest (BioVentures), Copenhagen, Denmark 70%Merifin Capital, Brussels, Begium 18%K Nominees, London, UK 6%Astellas Venture Management, Menlo Park, USA 4%All others 2%


2004 2005 2006 2007 20081922 25 25 25Employment


Companyvaluation


1 12/2001 Seed Privateer (various) (721) 7212 8/2002 Startup / Early Stage BankInvest (BioVentures), Copenhagen, Denmark (4300);

Merifin Capital, Brussels, Belgium (1200); K Nominees, London, UK (700)

6200 6200

3 9/2004 Expansion / Development BankInvest (BioVentures), Copenhagen, Denmark (6200); Merifin Capital, Brussels, Belgium (1600); K Nominees, London, UK (400)

8200

4 3/2006 Expansion / Development BankInvest (BioVentures), Copenhagen, Denmark (4300); Merifin Capital, Brussels, Belgium (1200); K Nominees, London, UK (400); Astellas Venture Managment (1400)

7300


Genetic Immunity Kft.



Country Hungary

Website www.geneticimmunity.comEmail

Address Fo u. 681027 Budapest

Phone +36 12019234Fax +36 12012817

Development and manufacturing of DNA based therapeutic vaccines with topical administration

Genetic Immunity (GI) is an innovative biotech company develops DermaVir, a platfrom technology for therapeutic vaccines. First product, a topical therapeutic vaccine against HIV/AIDS is under clinical development. The phase I clincial trial is succesfully accomplished in Hungary, phase I/II trials are running in USA (4 clinical sites) and Sweden. Founder of the company and the leader of the development of DermaVir, is Prof. Julianna Lisziewicz, received EU Marie Curie Chair support for the development of DermaVir.GI has been built an innovative cluster to develop theraputic vaccines for unmet medical needs like HIV, Hepatitis C, cancer and allergy with financial support of the EU and Hungarian government.The Vaccine Therapy Cluster (VTC) is the first biotechnology cluster aiming to integrate •basic and applied R&D activities •pre-clinical and clinical development •GMP manufacturing facility and •business development

on the field of vaccine therapy.The collaboration between innovative biotech companies, universities, academian institutes and clinics wordlwide will be enhanced by SMEs specialized in different additional areas like regulatory affairs, IP protection and data management, ISO quality management and much more. VTC is an open cluster and welcomes every new ideas and technologies at any development stages.The ambitious goal of GI is to bring the first therapeutic vaccine against HIV/AIDS to the market and become the core of a new biopharmaceutical industry of therapeutic vaccines.

Technology/Product AdvantageDermaVir is a proprietary platfrom technology for DNA based thearpeutic vaccines. The topical administration (patch) targets epidermal Langerhans cells (LC). The special construction of the vaccine builds nanoparticle entering into the LC. The vaccinated LC induce specific cell mediated imune response in the lymph node and produce memory T cells to kill HIV infected cells.


Founded 1992


Business Activity

Key Customerslarge pharma companies

Key PartnershipsHungarian Academy, EU Marie Curie Chair Prog, Karolinska Institutet, NIH (USA), ACTG (USA), PACTG (USA)

Key Competitorsnone

Dr zsolt lisziewicz, Chief Executive OfficerEmail: [email protected]: +36 12017725

Presenter


Genetic Immunity Kft.



AchievementsDermaVir is successful acomplished the phase I clinical trial. There are no significant side effects. Now we are in the phase II clinical trial in Hungary, Sweden and in the USA. 38 international patents protect the related IP.

Other informationWe received >7 Mio EUR funding from the EU and the Hungarian government to develop and upscale the GMP manufacturing processes and build the manufacturing facility in Hungary. The manufacturing facility will be ready to use in early 2008.

Financing Sought/Investment PlanGenetic Immunity Kft. is seeking Expansion / Development and Startup / Early Stage financing to the amount of 15 M Euro in exchange for 10% of the company shares.

Finishing Phase II clinical trial in EU and USA.

Genetic Immunity Kft. is seeking partnership for Joint Research & Development, Product development and Sales.

We are looking for pertners who are able to finance and co-develop and distribute the DermaVir HIV vaccine against HIV clades prevalent in China. Other appliaction of the platfrom technology against Hepatitis C, Malaria, etc. is optional.

Partnership Sought

ShareholdersGenetic Immunity LLC 95%private persons 5%


Companyvaluation


1 8/6 Seed 24000


GENTEST s.r.o.



Country Czech Republic

Website www.gentest.czEmail [email protected]

Address Na Hrebenkach 4160 00 Prague

Phone +420 724143945Fax +420 257324281

Genetic tests of disposition to illnesses to improve quality of life and to enable longer lifetime

1) target market: middle and top management of companies business model: we offer genetic tests to companies to test disposition of their employees to illnesses: a) incidental with their working activities (for example disposition to deep venousis trombosis); it helps to protect employee`s health in working process b) not incidental with their working activities (like disposition to different typies of cancer) as a benefit for them (a good prevention could avoid a serious illness)both help companies to improve and/or maintain a good relation with employees (a test result is strictly confidential and it is received by a tested person only)2) target market: ordinary public business model: we offer genetic so called "home tests" to ordinary public(for example disposition to different typies of cancer) using pharmacies as a sales chain; tests are for the same reason as in the case of companies - a good prevention could avoid a serious illness - and again a test result is strictly confidential and it is received by a tested person only

Technology/Product Advantagenone


Achievementsstarting from scratchcreation of a new market

Founded 2003


Business Activity

Key Customersmultinationals, insuarance companies, ordinary public

Key Partnershipsconfidential

Key Competitorsnone for home tests, referential laboratories

Mr Ilja Mracek, Chief Executive OfficerEmail: [email protected]: +420 724143945

Presenter


GENTEST s.r.o.



Other information

Financing Sought/Investment PlanGENTEST s.r.o. is seeking Startup / Early Stage and Expansion / Development financing to the amount of 16 M Euro in exchange for a to be discussed % of the company shares.

GENTEST s.r.o. is seeking partnership for Other.

GENTEST s.r.o. is looking for a partner with whom it can set up a joint venture company use for penetration of China market.

Partnership Sought

Management TeamMr Ilja Mracek, Chief Executive Officer

I started my business carrier as a consultant (McKinsey&Company). I work as a consultant for more than 10 years and then I switched to an operational role as Financial Directors and General Directors. Finally I became the CEO of the GENTEST.

ShareholdersIlja Mracek 100%


2004 2005 2006 2007 2008TurnoverEmployment


Companyvaluation


1 7/2003 Seed Ilja Mracek (50) 50


Global Biopolitics Research Group




Website www.ioh.uea.ac.uk/biopolitics/Email [email protected]

Address Edith Cavell BuildingUniversity of East Anglia

Norwich NR4 7TJ

Phone +44 1603597132Fax +44 1603597019

Research / analysis of biotechnology policy and regulation, focusing on new health technologies

Academic research group, based at the University of East Anglia in the UK.

We have expertise in all aspects of policy relating to health biotechnology, including funding models (public and private) as well as ethical and regulatory issues. Our research is global, and our group includes partners in Europe, the US and Asia-Pacific.

We have strong international links and ties with the VC and science community. We regularly engage in dialogue with policymakers, researchers and the enterprise community about the implications of our work.

Technology/Product AdvantageExpertise in international political economy and finance as well as bioethics and science and technology policy.

International partnerships (Europe, US, Asia-Pacific).

Links with science community, VC community and policy makers.


AchievementsOur research agenda focuses on the global dynamics of policymaking regarding new health technologies. Current GBRG research projects include the global regulation of human embryonic stem cell science, for which we have compiled a database covering national regulatory regimes and emerging structures of transnational governance, as well as data on the funding of research and prospects for commercialization. We have strong international links and regularly engage in dialogue with policymakers, researchers and the enterprise community about the implications of our work. For further details, please visit www.ioh.uea.ac.uk/biopolitics

Founded 2005


Business Activity

Key CustomersUK government, ESRC, Venture capital community, Scientists

Key PartnershipsEESCN , University of York, SATSU, Univ of Cambridge, CGKP, UNSW, Australia, University of Vienna, U of Michigan (Ford Sch)

Ms Amanda Dickins, Senior Research AssociateEmail: [email protected]: +44 1603591020

Presenter


Global Biopolitics Research Group



Management TeamProf Brian Salter, Director

Brian Salter is Professor of Biopolitics at the University of East Anglia and Director of the Global Biopolitics Research Group. A public policy analyst, he has published eight books and over 100 academic articles on science, health and education policy. He has acted as policy adviser to the European Union, international funding bodies, the UK National Health Service and professional bodies such as the UK's General Medical Council. Most recently his work has dealt with international issues of governance in the introduction of new health technologies, the emerging pressures from citizens and consumers, and the limits of scientific advice in regulation. Currently he is working on the contribution of bioethics to the resolution of cultural tensions in human embryo science.

Ms Amanda Dickins, Senior Research AssociateAmanda Dickins joined the Global Biopolitics Research Group as a Senior Research Associate in July 2005. She works on the regulation and management of the life sciences and health biotechnology, focusing on human embryonic stem cell research and covering issues such as intellectual property rights, pathways to commercialization and the financing of research.

Prior to joining the Global Biopolitics Research Group, Amanda was a Senior Research Associate with the Global Economic Governance Programme at the University of Oxford and a Research Fellow at the Centre for Business Research at the University of Cambridge. Amanda is trained in Economics and International Relations and has degrees from Oxford, London and Princeton.

ShareholdersESRC 50%UEA 50%


Heidelberg Technology Park GmbH



Country Germany

Website www.technologiepark-heidelberg.de

Email [email protected] Marktplatz 10

69117 Heidelberg

Phone +49 62215820500Fax +49 62215820990

The Park is an international Science Park focused on biotechnology and environmental technologies.

The Heidelberg Technology Park, founded 1985, was the first Biopark in Germany, located on the university campus in an excellent scientific environment. Since then the Park has become the center of the Heidelberg BioCluster creating a network of actors from science, business and administration. In 2005 the Environmental Park has been founded as a new part of the Technology Park. At present there are about 70 companies and institutions working in the park with about 1000 em-ployees. Regarding the biotech scene in the whole Heidelberg area there has been a dynamic growth. The scientific background is created by eight world class research institutions and universi-ties, including Heidelberg University, the German Cancer Center and the European Molecular Biol-ogy Laboratory. The economic backbone consists of nine pharmaceutical companies including Roche Diagnostics, Mannheim, BASF, Ludwigshafen and Merck, Darmstadt.The Heidelberg Technology Park is not only an incubator for start-ups, but also an environment for companies at any stage and any phase of growth. The Park offers and organizes all needed services for premature business ideas and projects, just started enterprises and growing companies, moving to their second, third or even further rounds of financing. The Park also welcomes "grown ups" and producing industrial partners. They all should be part of an adding value system in the life sci-ence industries. This includes access to support in many fields of biotech like patent law, tax and economic law, human resources, education, acquisition and mediation, management and financial concepts etc. as well as the organization of conferences, fairs and partnering events. The "hardware" of the Technology Park is the offer of around 50,000 m² lab and office space. The "software" of the Park is created by a regional, national and international network of information and cooperation. About 200 value adding partners are Associated Members of the Heidelberg Technology

AchievementsKey references in China are 4 Chinese sisterparks:Beijing, Tsinghua Science ParkJinan, Jinan Hi-Tech Development ZoneQingdao, Qingdao Hi-Tech Industrial ParkShanghai, Shanghai Caohejing Hi-Tech Park

Founded 1985


Business Activity

Key Customersstart-ups companies, spin-offs

Key PartnershipsIASP Malaga, Spain, BIO, Washington, USA, WTA, Daejeon, South Korea, CEBR (EU-Network)

Dr Klaus Plate, Chief Executive OfficerEmail: [email protected]: +49 62215820500

Presenter


Heidelberg Technology Park GmbH



Other informationThe Heidelberg Technology Park is looking for companies and institutions from China that want to locate in the Heidelberg BioCluster or work together with partners based here.

The "software" of the Park is created by a regional, national and international network of information and cooperation. About 200 value adding partners are Associated Members of the Heidelberg Technology Park. They offer any kind of support and services.

Partnership Sought

Management TeamDr Klaus Plate, Chief Executive Officer

Director of General Administration and Economic Development, City of Heidelberg CEO, Heidelberg Technology Park

Born Nov. 24, 1942; Law studies at the Universities of Hamburg, Freiburg/Br. and Göttingen, Germany.Qualification as lawyer and judge since 1972. Since 1973 City Administration of the City of Heidelberg. Director of the Department of General Administration and Economic Develop-ment. Managing Director of the HWE Heidelberger Wirtschaftsentwicklungsgesellschaft mbH (Hei-delberg Economic Development Corporation).

CEO of the Technologiepark Heidelberg GmbH (Heidelberg Technology Park), the first Biopark in Germany, since 1994.International President 2000 - 2002 of the International Association of Science and Technol-ogy Parks (IASP).Member of the Advisory Committee of Zhongguancun Science Park 2000 – 2002, Beijing, China.Member of the Board of the Council of Biotechnology Center, Biotechnology Industry Or-ganization (BIO), USA.

Dr Marion Kronabel, Assistant Chief Executive OfficerBorn May, 11. 1962; Biology studies at the University of Darmstadt, Germany.Qualification as Diplom-Biologist since 1987.1987 – 1991 Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), Heidelberg1991 – 1998 positions in the pharmaceutical and diagnostical industry1988 – 2000 conception, planning and organisation of seminars and conferences for specialists in the pharmaceutical industry

Assistant Managing Director of the Technology Park Heidelberg GmbH, the company running the first Biopark in Germany

ShareholdersCity of Heidelberg 98%Chamber of Industry and Commerce 2%


Hybys Kft.



Country Hungary

Website www.hybys.huEmail [email protected]

Address Soroksári Str. 48. 1095 Budapest

Phone +36 12156440Fax +36 12163879

Research on the filed of plant and bacterial biotech. - NON GMOWater cleaning and recycling

Activity filed: - biological research on the field of plant andbacterial biotechnology - NON GMO ! - cleaning and recycling of waste water (unique mobile solution)

1. RESEARCH AND DEVELOPMENT I. Bacterial inocula development for plant growth promotion and nitrogen supply and as well as for facilitate composting process. Registered Product brand name is: SYMBION - BIO-fertilizer product (using mainly nitrogen-fixing bacteria)II. Plant biotechnology for producing nitrogen self-nourishing plants (non-GMO!) using our novel processes (e.g. for biomass plants) Product : air NITROGEN fixing BANANA

III. Unique plant on the World Flower Market Product :LIGHTING FLOWERIV. Nitrogen fixing Miscanthus gigantheus Product :NITROGEN FIXING ENERGY PLANT V. Modified high frequency reverse osmose in water recyclingProduct: 3-TM - high capacity mobile(container) unit

2. PRODUCTION I. Bio-fertilizer (SYMBION) – start with the production(fermentation) facilities II. Own micropropagation laboratory for multiplying N fixing BananasIII. Own technology for microprpopagation of N fixing Miscanthus G. IV. 3-TM container water cleaning and recycling unit.

Technology/Product Advantage SYMBION- is a 23 bacterias containing BIO FERTILIZER.

- because of the large No.of bacteria species the efficacy of SYMBION is under extreme conditions detectable on filed results N fixing BANANA - the micropropagated banana plantlets are patogen free- min. +25 % by new plantlet growing - saves 90 % of nitrogen fertilizer use- high positive environmental effect (nitrite-nitrate poison)

LIGHTING PLANT- unique plant on the world flower market BIOMASS PRODUCTION N-FIXING MISCANTHUS - Miscanthus is the most cost effective solution for large scale renewable biomass production- complete BIOMASS production has been developed by HYBYS using N fixing Miscanthus.3-TM WATER RECYCLING UNIT - mobile or stationary unit - capacity 5-10 times higher that the traditional reverse osmose


Founded 2000


Business Activity

Key CustomersBanana-large scale produc, flower world market, power station using BIO

Key Partnerships

Dr Imre Horváth, Founder owner, proprietor and researcher Email: [email protected]: +36 209538305 - Ext: 155

Presenter


Hybys Kft.



AchievementsProductSYMBION – BIO fertilizerPatent: nitrogen fixing banana References: SYMBION –large scale production resultsBIOMASS - N-FIXING MISCANTHUSPatent : nitrogen fixing Miscanthus - ongoingMiscanthus production and network system developed Ongoing co-operation with power plants and local state heating centers for biomass production3-TM WATER RECYCLING EQUIPMENTPatent : ongiong DEMO unit : availeble, ready for the market

Financing Sought/Investment PlanHybys Kft. is seeking Stock market listing and Expansion / Development financing to the amount of 1.8 M Euro in exchange for 49% of the company shares or negotiable .

Looking for partner to realize on the market the results of R+D activities.

Hybys Kft. is seeking partnership for Sales and Other.

Hybys Ltd. looking partners for buying technologies and products like- SYMBION (bio fertilizer and its production in mobile unit) - Wather cleaning system technology and product

Partnership Sought

Raphold Rt. - Research , ELTE – (technical) UNIVER, VERT – „VÉRTES“ Power Pl, Kraftszer - atel Group , Greeninvest Kft.

Key Competitorsmicroporagation labs. , flower producers, other biomass producers –, water filter producer

Management TeamDr Imre Horváth, Founder owner, proprietor and researcher

Main Profile Excellent multi-skilled R&D manager, broad experience in the field of biotechnology and life sciences, with additional good organization skills, combined with innovative thinking. Experiences o engineering business processes at SME and managing business operation of multinational companies, o establishing and operating new sales network systems,o research and development activities in the field of biotechnology and life sciences, o managerial experiences at corporate enterprises o organizing, financing and participating in different R&D projects,o building up international R&D co-operation

Dr Szilárd Sándor Varga, Managing Director Md. owner, researcher

ShareholdersDr Szilárd Sándor VARGA 40%Dr Imre Horváth 37%Hoffmann Ltd 23%


2004 2005 2006 2007 200894306 528 1811 3208Turnover450 77 692 1077EBIT

196158 327 519 712Equity1010 15 60 100Employment


Companyvaluation


1 12/2006 Expansion / Development lighting flower (400); SYMBION (400); Banana (100); Miscanthus (500); 3-TM Water Recycling (400)

5000 1800


Intercell AG



Country Austria

Website www.intercell.comEmail

Address Campus Vienna Biocenter 6A-1030 Vienna

Phone +43 1206200Fax +43 120620800

Research & Development of novel vaccines against infectious diseases

Intercell AG is a fast growing biotechnology company with a clear strategy and focus on the design and development of novel vaccines for prophylaxis and treatment of diseases with substantial unmet needs. The Company’s unique position is based on the combination of antigens and immunizers (adjuvants) derived from its proprietary technology platforms and its in-house GMP facilities. Intercell’s technology has been endorsed by collaborative agreements with a number of global pharmaceutical companies, including Sanofi Aventis, Merck&Co., Inc., Scigen Ltd. and the Statens Serum Institut. The Company has a broad development pipeline with a vaccine for Japanese Encephalitis about to enter Phase III, a vaccine for Hepatitis C undergoing Phase II trials, and five products focused on infectious diseases in the pre-clinical phase. Intercell is listed on the Vienna stock exchange under the symbol “ICLL”.

Technology/Product AdvantageThe work of Intercell is based on two technological programs – the Antigen Identification Program and the adjuvants program (the “Immunizers”). Intercell has created a program for identifying most, vaccine suitable antigens for a whole range of pathogens. In pursuit of this goal, Intercell’s Antigen Identification Program uses state-of-the-art molecular and serological methods to identify those structures of the pathogens, which are recognized by the human immune system.


AchievementsIntercell AG acquired a multi-purpose biologics manufacturing plant in Livingston, Scotland in March 2004. The manufacturing capacity will be used for its late stage Japanese encephalitis vaccine and for its vaccine pipeline resulting from its bacterial Antigen Identification research and development programs. Intercell AG and Aventis Pasteur extend their collaboration on the development of bacterial vaccines based on the success in identifying relevant antigens to treat a bacterial disease.

Founded 1998


Business Activity

Key PartnershipsSanofi Aventis, Statens Serum Institut, Merck&Co, Inc.

Prof Alexander Von Gabain, Chief Executive OfficerEmail: [email protected]: +43 1206200

Presenter

Management TeamProf Alexander Von Gabain, Chief Executive Officer

Alexander von Gabain is CEO and co-founder of Intercell AG in Vienna. Earlier he was Chairman of the Department of Microbiology and Genetics at the renowned research Campus of the Vienna Biocenter/IMP. Alexander von Gabain’s scientific career has taken him to outstanding institutions such as the Universities of Heidelberg and Stanford and to the Nobel Karolinska Institute in Stockholm where he served as professor of medical biotechnology and later as foreign adjunct professor. His research interest is in the field of microbial gene expression, host-parasite interactions and immunology. The results of his research in gene expression have found their way into advanced textbooks on bacterial physiology. He is a member of numerous professional organizations, co-publisher of scientific journals and by working as a consultant to pharmaceutical companies and organizing prestigious conferences, he has established a range of worldwide contacts.

Dr Werner Lanthaler, Chief Financial OfficerWerner Lanthaler is the Chief Financial Officer at Intercell AG. Earlier he was Head of Marketing and Communications of the Federation of Austrian Industry and before that, a senior management consultant at McKinsey & Company International. His academic career includes doctorates from the Economics University of Vienna and Harvard University, USA. He has considerable experience of labor and capital markets in the USA, South America and Europe. Werner Lanthaler is also the author and co-author of a wide range of books and articles.At Intercell his responsibilities comprise Finance, Administration, Human Resources, Public Affairs and Investor Relations.


Intercell AG



Intercell AG is seeking partnership for Product development, Joint Research & Development and Other.

Partnership Sought

Production, Research, Licensing, Acquisition, Knowledge PartnerIntercell is very interested in establishing contacts with Chinese academia, but also with the country’s industry. Our product portfolio comprises disease targets that fit perfectly to the health car needs of China. Novel vaccines in advanced development stages against JEV, HCV, Pneumococcus and Mycobacterium Tuberculosis are only a few examples where the biotech arenas of China and Europe have a great potential to meet the health care and commercial interests of both continents. As European biotech company that is well linked into the USA, India and Australia, we are particularly eager to establish scientific, commercial and financial partnerships with a country whose science, biotech and health care sector is internationally seen with great respect.

Partnership Info

Dr Gerd Zettlmeissl, Chief Operating OfficerGerd Zettlmeissl is serving as the Chief Operating Officer at Intercell AG since autumn 2001. Previously, Gerd Zettlmeissl was the international Head of Industrial and Quality Operations at Chiron Vaccines, and CEO and Managing Director of Chiron Behring GmbH&Co – the fully integrated German subsidiary of one of the world‘s largest biotechnology firms, Chiron Corporation. He is the author of numerous scientific publications and is inventor/co-inventor of numerous patents in the field of biotechnology. At Intercell he is responsible for Business Development and Product Development.

Dr Michael Buschle, Chief Technical OfficerMichael Buschle is Chief Scientific Officer and one of Intercell’s Co-founders. His scientific and industrial career includes work at the Royal Free Hospital School of Medicine, London, UK, the St. Jude Children’s Research Hospital, Memphis, TN, USA and at the pharmaceutical company Boehringer Ingelheim. Michael Buschle is the holder of several patents in the field of vaccines and biotechnology. He is responsible for the company’s Core Research activities leading to development candidates and the facility in Livingston.

ShareholdersMPM CapitalAPAX PartnersNomura Ltd.TVMKapital & WertGlobal Life Science Ventures


2004 2005 2006 2007 2008117Employment


Companyvaluation


1 12/1999 Seed TVM; Kapital & Wert 300002 11/2000 Startup / Early Stage Apax Partners Funds ; Nomura Ltd. 270003 11/2003 Expansion / Development Global Life Science Ventures; MPM Capital 43500


Jerini AG AG



Country Germany

Website www.jerini.comEmail [email protected]

Address Invalidenstrasse 13010115 Berlin

Phone +49 30978930Fax +49 3097893105

Jerini is in the business of discovering and developing drugs both independently and with partners.

Jerini is a pharmaceutical company based in Berlin, Germany, focusing on the discovery and development of novel peptide-based drugs. Using its proprietary technology platform, Peptides-to-Drugs (P2D), Jerini pursues disease indications for which limited, inadequate, or no treatment options exist. As a result, Jerini has established a drug pipeline composed of its own programs as well as others in collaboration with partners. Jerini's commercialization strategy is to market new drugs in niche indications independently and in larger indications with partners.

Technology/Product AdvantageJerini's proprietary technology platform, Peptides-to-Drugs (P2D), facilitates the development of drug candidates from peptides (small protein pieces). Drugs developed through P2D can take two forms, injectable (peptidomimetic) or orally available (small molecule), depending on the disease indication. Injectable drugs are generally developed for acute indications, drugs taken orally are often preferable for chronic or long-term therapy.


AchievementsUpcoming Milestones:Report top line Phase III hereditary angioedema data: Q3 2006Submit marketing authorization applications: Q4 2006Start of Phase I AMD clinical trial: Q4 2006/Q1 2007Start of Phase IIa drug-induced angioedema trial: Q4 2006/Q1 2007

Founded 1992


Business Activity

Key PartnershipsAlcon Research Ltd., Baxter Healthcare, Kos Pharmaceuticals Inc., sanofi-aventis

Prof Jens Schneider-Mergener, Chief Executive OfficerEmail: [email protected]: +49 3097893121

Presenter

Management TeamProf Jens Schneider-Mergener, Chief Executive Officer

Jens Schneider-Mergener founded Jerini in 1992, drawing on expertise and technology developed in his research group at the Charité (today’s joint medical center of Berlin’s Humboldt University and Freie University) and served as a consultant to the company. In 2000, he assumed the role of Chief Executive Officer to lead Jerini’s transformation into a pharmaceutical company, focusing on the discovery and development of innovative drugs. Dr. Schneider-Mergener has guided the company through all stages of its growth and been responsible for the acquisition of over 130 million euro in equity capital. He has assembled a proficient Management Board and gradually built Jerini into a talented and cohesive team of more than 130 employees. After receiving his undergraduate degree in chemistry and his PhD in biochemistry, Dr. Schneider-Mergener conducted post-doctoral research at the CaliforniaInstitute of Technology for three years. In 1990, he joined the faculty of the Charité and in 1999 received a professorship in biochemistry.


Jerini AG AG



Other informationCurrently, Jerini offers the following opportunities:Partnering of ophthalmology programs including development candidate JSM 6427 for age-related macula degeneration and other fibrotic eye diseasesPartnering of inflammation program including small organic & peptidomimetic drug candidates e.g., JSM 7717 for organ fibrosis, graft rejection and other inflammatory diseasesPartnering of Jerini’s PD2 discovery platform for targets specified with partners

ShareholdersOther 46%HealthCap 17%TVM 15%DWS Investment GmbH 9%3i 7%Kos Pharmaceuticals, Inc. 6%


2004 2005 2006 2007 200895516422Turnover

-18557-11996EBIT8232513061Equity

11394Employment


Companyvaluation


1 10/2001 Expansion / Development 101202 7/2002 Expansion / Development 100003 6/2004 Expansion / Development Healthcap; 3i; TVM; Polytechnos; Sanders Morris Harris 310004 2/2005 Expansion / Development 155005 11/2005 Stock market listing IPO-Financing 496006 11/2005 Expansion / Development licencing partner's equity investment 10000


Kinesis Pharma BV N.V.



Country Netherlands

WebsiteEmail [email protected]

Address Lage Mosten 294822 NK Breda

Phone +31 765480648Fax +31 765421777

Consultancy in development of drugs and biologics

Kinesis Pharma aims to facilitate a fast and high quality drug and biologics development process in close collaboration with the CMC, preclinical and clinical R&D departments of pharmaceutical and biotech companies through consultancy and contract research services

Technology/Product AdvantageWith its broad competence in drug and biologics development, Kinesis can perfectly work participate in a virtual company setup. Especially for small companies the availability of senior people in the core areas of drug development is essential and through our services affordable.


AchievementsPatents:

Founded 1997


Business Activity

Key PartnershipsBig pharma, Government organisations, Small start ups

Dr Kees Groen, Chief Executive OfficerEmail: [email protected]: +31 765480648

Presenter


Kinesis Pharma BV N.V.



Kinesis is looking for pharma and biotech companies in need of the services described above, who's strategy it is to fill in their development needs on a flexible basis and with experienced people.

Partnership Sought

ShareholdersKinesis Holding BV 100%


Companyvaluation


1 9/1997 Startup / Early Stage Kinesis Holding BV


KitoZyme



Country Belgium

Website www.kitozyme.comEmail [email protected]

Address Parc industriel des Hauts Sarts- Zone 2Rue Haute Claire 44040 Herstal Liège

Phone +32 42598500Fax +32 42598509

Production of vegetal biopolymers for application in medical, cosmetics,nutraceutic, wine industry

The specialties market is benefiting from KitoZyme’s innovative vegetal biopolymers, safe and environmentally friendly.Each biopolymer from KitoZyme‘s range is dedicated to high added value applications, with specific features such as:• Pharmaceutical and medical devices (drug delivery, surgical aids, wound care, tissue engineering, …)• Personal care and cosmetics (antimicrobial, skin healing,anti-aging, preservatives )• Nutraceutics (weight loss, cholesterol lowering, pain relieving in arthritis condition, )• Wine industry (clarifying and detoxifying properties - Heavy metals and mycotoxins )KitoZyme's range of functional polysaccharide is :• Ultra-pure chitosan (GMP-production unit)• Pure chitosan• Pure chitin-glucan

Technology/Product AdvantageKitozyme's competitive advantage is to be able to extract chitosan and chitin-glucan from fungal biomasses, that are by-products of biotech industries and truly renewable biomasses. That is a world-wide patented exclusivity. Kitozyme products offer various conclusive competitive advantages for the customers : the "non animal" origin, the quality and the purity of the product and a more constant quality of the raw material for a competitive price. The fungal chitosan avoids the risk of allergy which has prevented crustacean chitosan from being fully exploited on the food, beverage and cosmetics markets so far.Furthermore the modular production process, offers the following advantages: the control of the molecular weight and the control of the deacetylation degree. Both qualities are rewarded by the customers.


AchievementsAwards : " Prix de l'innovation technologique 2005 en Wallonie " (price rewarding the more innovative company in 2005 in Wallonia, Belgium)Patents:- Cell wall derivatives from biomass and preparation thereof: WO03068824- Use of fungal biomass’ extract as technological auxiliary for the treatment of food liquids:FR05.07066-One in preparation on the application side.Successful industrial piloting completed.Quality management: production under cGMP conditions and ISO Standard

Founded 2000


Business Activity

Key CustomersNegotiations in progress

Key PartnershipsUniv. Liège, Univ. Montpellier, DSM

Key CompetitorsPrimex, Cognis, Carmeda, Novamatrix, France chitine, Heppe

Mr Hugues Bultot, Chief Executive OfficerEmail: [email protected]: +32 42598500

Presenter


KitoZyme



Financing Sought/Investment PlanKitoZyme is seeking Expansion / Development financing to the amount of 3 M Euro in exchange for a to be discussed % of the company shares.

We plan to use this investment to build a new plant for the production of "pure vegetal chitosan" use in the cosmetic market and nutraceutical market.

KitoZyme is seeking partnership for Distribution and Product development.

Kitozyme is entering on the market and is completing the set up of an international distrbution network on the cosmetic, nutraceutic, wine, medical adn pharmaceutical markets.KitoZyme is also willing to initiate collaborations for development of news applications and product range diversification.KitoZyme is seeking new investors for the construction of a new plant and for the extension of the product range.

Partnership Sought

Management TeamMr Hugues Bultot, Chief Executive Officer

He is a graduate in law and management. Hugues has a good grip on finance techniques and partnerships and is well introduced in the hitech and biotech circles.As the CEO of KitoZyme, he is in charge of the business development and the administrative and financial matters.

Dr Sandrine Gautier, Chief Scientific OfficerSandrine has an Degree in Chemical Engineering, National Institute of Applied Sciences, Rouen, France and a Ph.D Doctorate in Polymer Science, Research Center on Artificial Biopolymers, University of Montpellier. She is responsible for product development and pre-marketing studies

ShareholdersSpinventure 54,39%Valois scrl 36,74%SRIW 12,25%Meusinvest 8,98%Innode ( www.innode.com)


2004 2005 2006 2007 20083575Turnover

-672258EBIT30501375Equity

158Employment


Companyvaluation


1 12/2000 Startup / Early Stage INNODE (94); Spinventure (32); 1262 12/2001 Expansion / Development Spinventure (69); INNODE (468); Meusinvest (87) 6243 12/2002 Expansion / Development INNODE (220); MEUSINVEST (155); SRIW (250) 6254 12/2002 Expansion / Development INNODE (bonds) (220); MEUSINVEST (bonds) (155); SRIW

(bonds) (250)625

5 12/2003 Expansion / Development INNODE (bonds) (625)6 11/2005 Expansion / Development VALOIS (1425); SRIW (250) 1675


Kurular



Country Bulgaria

Website www.bidas.comEmail

Address 1 "Dragalevska" Str., "Lozenetz" Dstr.1407 Sofia

Phone +359 28684282Fax +359 28684282

Bidas’ belief in the “ Continuous Improvement In Service Quality”

Companies from various product groups. Our products are used as ingredients in various end products such as yogurt, pastry, jam and pizza. Bidas also has the facility to repack products under private label.

Technology/Product AdvantageFreezing fruits & vegetables by IQF technology shelf life of 24 months, Bidas’ current Frozen Fruit and Vegetables production capacity stands at 20,000 mt Products can be packed in 10 kg, 20 kg and 500 kg cartons for industrial consumption as well as 2.5 kg , 1 kg and 454gram PE bags for the retail market


AchievementsTotal Quality Management” by TSE EN ISO 9001: 2000 , EFSIS “Higher Level Certificate of Conformity” , OU Cosher and HACCP

Founded 1976


Business Activity

Key Customersfrom Germany, Belgum

Key PartnershipsElsner Sofia, Lines Hollding Co, RANSON, ARDO N.v., PINGUIN N.v.

Key Competitorssome companies from BG , market

Ms Ivelina Kapralova, ManagerEmail: [email protected]: +359 28684282

Presenter

Management TeamMs Ivelina Kapralova, Manager

Graduated - TV Jurnalism - Sofia University "St. Sv. Kliment Ohridski", Spetialisations - USA - Marketing, Germany - Network marketing, Master - JICA Project - Global management


Kurular



Financing Sought/Investment PlanKurular is seeking Expansion / Development and Pre-IPO Financing financing to the amount of 0.7 M Euro in exchange for 10% of the company shares.

For development the business in BG.

Shareholders 2,500,00- Belgum 21%

1,800,00 - Germany 10%


Companyvaluation


1 12/2005 Stock market listing ECOFROST Co. (7000)


Merck Sharp & Dohme (China) Ltd.



Country China

Website www.merck.comEmail

Address Units 3-4 on level 7,Office Tower E3,THe Towers,Oriental Plaza100738 Beijing

Phone +86 1058167600Fax +86 1085188539

Global research-driven pharmaceutical company

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Merck discovers, develops, manufactures and markets medicines and vaccines in more than 20 therapeutic categories. Headquartered in Whitehouse station, N.J. (USA), Merck employs approximately 61,500 people worldwide, conducts research in 10 major research centers and operates 31 production facilities and 17 distribution centers in 25 countries. In 2205, Merck's global sales were $ 22 billion.

Founded


Business Activity

Dr Peter Wang, Senior DirectorEmail: [email protected]

Presenter

Management TeamDr Peter Wang, Senior Director

2005 now Senior Dir, External Scientific Affairs, China. Responsible for products licensing with external partners in China.2005 Vice President, Oncology Business Unit, Eli Lilly China

As head of Business Unit of Oncology, in charge of the most important and largest business of Eli Lilly in China by leading sales & marketing organizations

2002 General Mager , Eli Lilly& Company, North China In charge of business operation which include Oncology, Neuroscience, Diabetes, Anti-infective and Women’s Health.

2000 District Sales Manager, Neuroscience Retail, New York, Eli Lilly & Company. Supervised a group of American Sales Representatives to promote Lilly’s anti-Schizophrenia drug, Zyprexa.

1999 Senior Marketing Consultant, Eli Lilly Headquarter, Indianapolis, Indiana. Successfully launched anti-diabetic oral drug Actos in major markets including US, South Africa and Australia.

1999 Manager, Brand Management, Global Marketing and Sales Organization, Eli Lilly Headquarter, Indianapolis, Indiana. Supervised product launch plans across multifunctional teams for various products.

1996 Medical & Regulatory Affairs Dir, Eli Lilly Asia Inc.In charge of all registration trials and other clinical research with major hospitals across China.

1993 Post-doctoral Research Fellow, Indiana University School of Medicine, Indianapolis, Indiana. Studied anti-asthmatic drugs.

1990 Visiting Scholar, Health Care Management Department, University of British Columbia, Canada. Studied Canadian Health Care Law and played a key role in several important health care reform projects.

1986 Chief Health Officer, Ministry of Public Health, People’s Republic of China. In charge of bilateral collaboration between Chinese and US/Canadian governments in multiple projects.


Merck Sharp & Dohme (China) Ltd.



Alliance with external partners are an integral and essential part of our long-term business and research strategy. Our goal is simply to purse the best scientific programs from both internal research and external collaborations.

Partnership Sought


MOLOGEN AG



Country Germany

Website www.mologen.comEmail [email protected]

Address Fabeck Str.3014195 Berlin

Phone +49 308417880Fax +49 3084178850

Develop treatments for high-unmet-need illnesses

MOLOGEN uses its proprietary DNA technologies to develop treatments for high-unmet-need illnesses. The focus is on cancer and infectious diseases. MOLOGEN was one of the first German biotech companies to go public. Shares are listed at General Standard Segment (ISIN DE0006637200).MOLOGEN is specializing in selected areas of Molecular Medicine. The areas of competence are gene expression and gene therapy. The company is dedicated to the development of DNA expression and technologies for human and veterinary applications, leading to products for genetherapy, and prophylactic and therapeutic DNA-based vaccines.MOLOGEN has developed special designs for "transfection vectors", the DNA bits that carry the message for gene therapy and genetic vaccination, which are safer, in the sense of "cleaner in their genetic content" than existing tools.MOLOGEN vectors also enable effects that can not be attained with "classical" DNA vectors (plasmids). The vectors are more efficacious and promote immune response that aid in preventing or fighting off infections for which no traditional vaccine is available.The MOLOGEN team, headed by Prof. Burghardt Wittig, has been involved in the first clinical trials in human gene therapy in Germany. The company already has set up a production capacity big enough to equip even large clinical trails with clinical grade material.Founded in 1998 as a Private Public Partnership, MOLOGEN is located on the Campus of “Freie Universität Berlin”, Germany, with total of 50 employees and has a subsidiary in Madrid, Spain, where one third of the team is employed.

Technology/Product AdvantageMIDGE® (Minimalistic Immunogenically Defined Gene Expression) System, developed and patented by MOLOGEN, only comprises the CMV promoter, the transgene and a poly-A site, giving them a characteristic small size. The nucleotides of the loops are suited for the covalent attachment of various molecules. The MIDGE® vectors are 50% - 80% smaller than plasmids and of linear covalently closed topology.

MIDGE® vectors overcome the efficacy and safety drawbacks of other gene transfer and expression systems. They are not toxic, even in high excess over clinically relevant doses, and do not generate anti-vector immune reactions. Most importantly, they do not integrate into the host cell genome. Yet, MIDGE® vectors lead to efficient and safe preventive or therapeutic gene expression. They can even be targeted into certain tissues. MIDGE – based DNA vaccines provide regular onset, specific and long-lasting protection against an encoded infectious agent (virus, bacterium or parasite).

dSLIM® is a non – coding DNA molecule comprising an immunomodulating conformation and non –methlylated CG – dinucleotide motif. dSLIM is a covalently closed dumbbell – shaped double stem – loop immunomodulater (dSLIM) that actives immune system cells. This agent provides an inflammatory – like environment and increases antigen presentation/ costimulation via HLA and CD80 up – regulation, which can be directed against viruses, bacteria or tumor cells.

The dSLIM immunomodulator has applications in complementing chemotherapy or immunization, and may also be useful in redirecting allergic processes. dSLIM was successfully tested in human cancer trials as addition to peptide – or cell – based vaccination.

Founded


Business Activity

Dr Matthias Schroff, Chief Operating OfficerPresenter

Management TeamDr Matthias Schroff, Chief Operating Officer

Mr Manuel Schmidt, Head Tumor Immuno Therapy Clinical Trials

Ms Youzhen Lin, Business Development


MOLOGEN AG



MOLOGEN AG would like to meet with you at Beijing. Based on their proprietary MIDGE® vector- and dSLIM® immunomodulator technologies, MOLOGEN is developing and out-licensing DNA-based vaccines and therapeutics against cancer and infectious diseases for human and veterinary application. MOLOGEN is seeking partnering opportunities for the development of preventive DNA vaccines, therapeutic cancer vaccines, siRNA therapeutics, out-licensing of product candidates and of technology platforms, contract manufacturing of cell-based products (GMP), preclinical contract research (GLP).

Partnership Sought


m-phasys GmbH GmbH



Country Germany

Website www.m-phasys.comEmail [email protected]

Address Vor dem Kreuzberg 1772070 Tübingen

Phone +49 +49-7071-794514Fax +49 7071794511

Production of functional membrane proteins, GPCR antibodies, structure analysis

m-phasys was established in 1999 as a university spin-off. The private venture capital-backed company is based in Tübingen within easy reach of the international airport at Stuttgart. The M-FOLD™ technology for the production of purified, functional membrane proteins is the basis of m-phasys' activities. Since operations started, this platform has been gradually expanded to new target families and transformed into a miniaturized, parallel format. The company, originally focused on the structure analysis of membrane proteins alone, recently added the generation of therapeutic GPCR antibodies to its business areas.

m-phasys' proprietary platform, M-FOLD™, is a generic method for the production of purified membrane proteins. Currently, the success rate in producing functional receptors is 75% as estimated from a large-scale study with 150 GPCRs. The protein is used as antigen in the generation of monoclonal antibodies and for structural analysis by X-ray crystallography and NMR.

m-phasys has successfully established a series of corporate partnerships in areas covering therapeutic antibody development, membrane protein structural analysis and drug discovery assay development. Its partners include multinational pharma companies such as Bayer and GSK, as well as biotech companies such as Cosmix, Flyion, Graffinity, and Medarex.The Company also collaborates with leading academic research institutes to help drive forward its programs.

A team of 18 researchers with excellent track records in membrane protein biochemistry, cell biology and structural biology are the basis for m-phasys' technical leadership in the field. The company is headed by its scientific founder, Hans Kiefer.

Technology/Product Advantagem-phasys' proprietary M-FOLD™ technology utilises an E. coli expression system designed to enhance expression and to direct the recombinant protein to cytosolic aggregates known as "inclusion bodies”. Yields using this method are typically between 5-50 mg per litre of cell culture medium. The aggregated recombinant protein is then taken through a series of proprietary purification and refolding steps to generate functional, native protein.

With M-FOLD™, multiple targets or multiple variants of a given membrane protein target can be produced quickly and in a parallel format. To date, more than 200 different GPCRs and ion channels have been cloned and expressed using M-FOLD™.

M-FOLD™ is covered by several patents in Europe, the USA and Japan.

M-FOLD™ is the basis of drug discovery technologies such as protein structure analysis and the generation of therapeutic antibodies directed against GPCRs.


Founded 1999


Business Activity

Key CustomersPharma and Biotech Co.

Key PartnershipsMedarex, Fraunhofer IME, ProspectPharma Inc.

Dr Hans Kiefer, Chief Executive OfficerEmail: [email protected]

Presenter


m-phasys GmbH GmbH



Achievements- German BMBF grant "Structure analysis of ion channels".

m-phasys is interested in partnering in two business areas:

1. Structure analysis of membrane proteins2. Therapeutic and diagnostic GPCR antibodies

On the technical side we are looking for partners with innovative capabilities in X-ray crystallography (applicable to membrane proteins), as well as for antibody generation technologies.On the business side, we are interested in joining marketing forces with companies offering structure biology and antibody production services. We also offer our services directly to pharma and biotech companies.Strategically, we look for M§A opportunities to either support future growth of the company or, alternatively, enable integration into a larger entity.

Partnership Info

Key CompetitorsGPCR Ab and service Co.

Management TeamDr Hans Kiefer, Chief Executive Officer

ShareholdersTechnoStartKfW BankengruppeGradus VentureGrazia Equity GmbHHeidelberg InnovationPrivate Investors


Companyvaluation


1 1/2005 Expansion / Development TechnoStart; KfW; Grazia equity; Gradus Venture; Heidelberg Innovation


Mucosis



Country Netherlands

Website www.mucosis.comEmail

Address Nijenborgh 49747 AG Groningen

Phone +31 503635246Fax +31 503634429

Vaccine Research and Development Company

Mucosis is a specialist company with a focus on development of nasal and oral (mucosal) vaccines to defeat infectious diseases. The mission of Mucosis is to improve healthcare worldwide, by developing highly effective and safe vaccines which can be administered at a maximum comfort level. As a dedicated vaccine development company, Mucosis aims to be the preferred partner for major vaccine companies in developing mucosal vaccines. Mucosis is applying it MIMOPATH™ technology to develop its own vaccines and is also offering its technology to partners for joint-vaccine development. Antigens are obtained from collaborations or from Mucosis’ own antigens screening and selection program.

Technology/Product AdvantageThe proprietary MIMOPATH™ technology of Mucosis enables vaccine formulation with built-in adjuvant activity and can be applied with all types of antigens. The resulting vaccine can be administered mucosal or parenteral. The technology is based on safe, food-grade, microorganisms and the resulting vaccine contains no recombinant DNA, no pathogenic, no toxic and no detoxified components. Furthermore, the production of the vaccines is relative easy and cost-effective.The MIMOPATH™ technology can be used in the development of new vaccines, in optimizing existing vaccines, reformulating injectable vaccines into mucosal (e.g. nasal) vaccines, and it can be used as booster following first-time injection.


AchievementsMucosis has developed the technology beyond proof of concept in murine challenge models. The technology has been protected with a world-wide patent portfolio, of which several applications already have been granted.

Founded 2006


Business Activity

Key Customersvaccine companies

Key PartnershipsBiomade Technology, University of Groningen, University of Nijmegen

Key Competitorsvaccine companies

Dr Hans Hektor, Chief Executive OfficerEmail: [email protected]: +31 503635246

Presenter


Mucosis



Financing Sought/Investment PlanMucosis is seeking Startup / Early Stage financing to the amount of 6.5 M Euro in exchange for a to be discussed % of the company shares.

To investment will be used to obtain proof of principle in humans and expand the current vaccine development.

Mucosis is looking for interested parties who want to co-develop vaccines or who have interest in formulating their vaccines and/or antigens withthe MIMOPATH™ technology. The technology is available for licensing and Mucosis can be hired to perform the vaccine development by contract.

Partnership Sought

Management TeamDr Hans Hektor, Chief Executive Officer

Dr. Hans Hektor (co-founder, CEO) has a strong background in biotechnology. He received his PhD in Microbial Physiology at the University of Groningen, followed by a fellowship at Harvard University. During his employment at Enchira Biotechnology Corporation in Houston, Texas, he was closely involved in the transformation of EBC towards a molecular evolution research and service company. In 2001 Hans Hektor joined Biomade Technology as programme manager, later becoming director of business development. He was appointed COO of Applied NanoSystems BV in 2003 to manage and exploit the patent portfolios generated by this development company. Hans Hektor is currently involved with the executive MBA program of Nimbas University.

Dr Kees Leenhouts, Chief Scientific OfficerDr. Kees Leenhouts (co-founder, CSO) received his PhD in biology at the University of Groningen. He spent two years at the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Italy to specialize in vaccine development. In 2000 he joined Biomade Technology as programme manager where he initiated several research programmes and established various national collaborative research projects in the area of vaccine development. Dr. Leenhouts is a co-inventor of Mucosis’ MIMOPATH™ technology.

ShareholdersBiomade TechnologyFounders/Management


NeuroSolutions Ltd




Website www.nsolns.comEmail [email protected]

Address PO Box 3517CoventryCoventry CV4 7ZS

Phone +44 8454500171Fax +44 8454500172

Contract research and drug discovery and development

Neurosolutions Ltd, established in April, 2001, is at the forefront of contract electrophysiological research and aims to provide clients with flexible and high quality services with fast turnaround that meets the needs of a wide range of biopharmaceutical companies. Neurosolutions Ltd has a large portfolio of clients ranging from start-ups to multinational pharmaceutical companies. NeuroSolutions Ltd supports and contributes to all aspects of preclinical drug discovery by using specialist electrophysiological technologies to identify specific drug targets, investigate drug mechanism of action and support lead development. Over the years, NeuroSolutions established a series of drug discovery programs and currently have a compound ready to go into clinical Phase I trial and a second compound awaiting for aproval for a Phase IIa trial.

Technology/Product AdvantageNeurosolutions Ltd supplies specialist techniques including whole cell recording, CNS slice recording, in vivo recordings from peripheral and central nervous system in a range of disease models such as neuropathic and inflammatory pain, epilepsy, neurodegenerative diseases and obesity. Neurolutions has accumulated considerable experience in drug discovery and development.


AchievementsIn 2005, NeuroSolutions was listed in the Australian Stock Market under the name of NeuroDiscovery Ltd (NDL) Two Patents are filed.NeuroSolutions has been awarded a Smart Grant and Technology Transfer Partnership (KTP) Grant from British Government Department of Trade and Industry (DTI).

Founded 2001


Business Activity

Key CustomersGSK, Lilly, Sepracor, Organon, Senexis, Xention

Key PartnershipsQuintiles/Aptuit, Sosei, Ampika

Key CompetitorsCerep, Porsolt & Partners, Holliston Pharma Test, NeuroLab

Dr Fei-Yue Zhao, Chief Technical OfficerEmail: [email protected]: +44 2476528367

Presenter

Management TeamDr Mark Treherne, Chairman

1979-1983, BSc. (Hons),Physiology. St Andrews, Fife, UK1983-1987, PhD. (MSD-funded), "Quaternary radioligand for H1-receptor", Department of Pharmacology, University of Cambridge, UK

1987-1990, Postdoctoral Fellow, “Glucose-sensing in the CNS”, Department of Pharmacology, Cambridge University & Parke-Davis, Cambridge, UK

1990-1992, Bozentrum Fellow, Department of Pharmacology, Biozentrum der Universität Basel, Switzerland (in collaboration with Ciba-Geigy, Hoffman La Roche and Sandoz)1992-1993, Visiting Research Scientist, Institute of Neurology, London, UK1993-1997, Senior Principal Scientist, Pfizer, Sandwich, UK1997-2001, Chief Executive, Cambridge Drug Discovery Ltd, Cambridge, UK


NeuroSolutions Ltd



Other informationNeuroSolutions is looking for partnering companies to outsource contract work and for companies interested in CNS drug discovery and development to co-develop new compounds.

Financing Sought/Investment PlanNeuroSolutions Ltd is seeking Expansion / Development and Pre-IPO Financing financing to the amount of 2 M Euro in exchange for business expansion and drug development.

NeuroSolutions will use the funds to invest in the current 2 compounds to go into clinical trials and other pre-clinical compound development. NeuroSolutions will also use this fund to expand the contract research business.

We are interested in finding collaborations/partnerships for subcontracting research work and joint-development of drug dicovery programs.

Partnership Sought

2001-2002, Commercial Director, BioFocus Plc, Cambridge, UK2002-2004, Chief Executive, Senexis Ltd, Cambridge, UK2002-date: Chairman, NeuroSolutions Ltd, Coventry, UK

Prof Dave Spanswick, Chief Executive Officer1988-1992, PhD, Chemical Neurotransmission in the Spinal Cord In vitro. University of Birmingham, UK

1992-1994, Canadian Research Fellow, Loeb Research Institute, Canada 1993, 95, 98, Visiting Scientist, Kurume School of Medicine, Japan

1995- 2000, Lecturer, Department of Biomedical Sciences, University of Aberdeen, UK2000-2004, Senior Lecturer, Department of Biological Sciences, University of Warwick, UK2004-date, Professor of Physiology, Warwick Medical School, UK

Dr Fei-Yue Zhao, Chief Technical Officer1984-1990, Ph.D., Neurophysiological Mechanisms of Inflammatory Pain, China Academy of Traditional Chinese Medicine,

Beijing, China1990-1994: Research Fellow/Senior Research Fellow, Department of Neurophysiology, China Academy of Traditional Chinese Medicine, Beijing, China1992-1994, Research Fellow, Department of Pharmacology, Tokyo Medical and Dental University, Japan1995-1998, Research Fellow, School of Biological Sciences, University of Bristol, UK1999-2001, Senior Scientist, Group Leader, Parke-Davis, Cambridge, UK.2001-present, Principal Investigator, NeuroSolutions Ltd, Coventry, UK

ShareholdersUniversity of Warwick 22%Kevin Lee 15%Mark Treherne 15%Dave Spanswick 15%Fei-Yue Zhao 15%


2004 2005 2006 2007 20081000700 1300 1800 2000Turnover

98 11 15 20Employment


Companyvaluation


1 8/2005 Stock market listing NeuroDiscovery (3000); 3000 3000


Novagali Pharma SA SA



Country France

Website www.novagali.comEmail [email protected]

Address 1 rue Pierre Fontaine,Genavenir IV

91058 Evry

Phone +33 0169874020Fax +33 0169874030

Novagali Pharma is a biopharmaceutical company focused on ophthalmology.

Novagali Pharma is an emerging biopharmaceutical company focused on ophthalmology that develops innovative products to treat eye diseases. Licensing, collaboration and alliance opportunities

Technology/Product AdvantageNovagali’s unique ocular technologies - Novasorb & Eyeject -enable the delivery of drugs into all segments of the eye - safely and with optimal comfort for the patient.

Achievementsmore than 16 patent families

Founded 2000


Business Activity

Mr Jérôme Martinez, Chief Executive OfficerEmail: [email protected]: +33 0169874020

Presenter

Management TeamMr Jérôme Martinez, Chief Executive Officer

Mr. Martinez began his career working as a pharmacist from 1983 to 1986 before becoming deputy director of Alliance Santé, a leading pharmaceutical distributor. In 1991, he headed a pharmaco-economics project for Roussel Uclaf in Tokyo, and later that year joined Laboratories Lavipharm as Vice President for corporatel marketing. He transferred to Princeton, NJ, USA to take up the position of Vice President of marketing and business development for Lavipharm Inc. In 2001, he joined Ethypharm Corp. as senior Vice President, business development and R&D for the U.S. and Canada. Back to France, he took a senior position at Laboratories Ethypharm before joining Novagali Pharma in January 2004.

Mr Jean-Sébastien Garrigue, Business Development Director


Novagali Pharma SA SA



Licensing

Partnership Sought


2004 2005 2006 2007 200815 30Employment


Companyvaluation


1 12/2000 Seed 37802 6/2004 Startup / Early Stage 140003 5/2006 Expansion / Development 26000


Omrix Inc



Country United States

Website www.omrix.com Email

Address 630 5th Avenue NY Suite 226510111 NY

Phone +1 2128876500Fax +1 2128876550

innovative biosurgical and passsive immunotherpaies products.

Our biosurgical product line includes products and product candidates that are used for the control of bleeding, or hemostasis, and other surgical applications. We compete in the active biosurgical hemostats market, which we believe is the fastest growing segment of the surgical sealant market. Our passive immunotherapy product line includes antibody-rich products and product candidates for the treatment of immune deficiencies and infectious diseases and for potential biodefense applications

Technology/Product Advantagevisit our website under "products".


Achievements

Founded 1995


Business Activity

Key CustomersEthicon,USA

Key CompetitorsBaxter Inc.

Mr Robert Taub, Chief Executive OfficerEmail: [email protected]

Presenter


Omrix Inc



Omrix Inc is seeking partnership for Distribution and Joint Research & Development.

Through partnership, OMRIX seeks to further develop, manufacture, and commercialize its products. We are currently collaborating with several companies whose own expertise complements our strengths in the areas of development and manufacturing. Through partnership we intend to focus on additional indications for existing products and product extensions, develop and launch products that integrate biological components and medical devices for the biosurgical market, and expand our core technology

Partnership Sought

Management TeamMr Robert Taub, Chief Executive Officer

Robert Taub has served as our president, chief executive officer and a member of our board of directors since the founding of OMRIX in 1995. Prior to establishing OMRIX, Mr. Taub was the cofounder of Octapharma A.G., a Swiss plasma fractionation and pharmaceutical company, which successfully introduced innovative plasma derivative products to the market. During his time at Octapharma, from 1983 to 1995, the company underwent a successful transformation from a start-up operation to an integrated manufacturing enterprise. He also founded a research and development group in Israel and initiated and directed the management of a biological fibrin sealant development project. Prior to Octapharma, Mr. Taub held various general management and sales and marketing positions with Armour Pharmaceutical, Revlon Health Care Group, Baxter Travenol Laboratories, Inc., now Baxter International Inc., and Monsanto Company. He has a B.A. in languages from the University of Antwerp and an M.B.A. from INSEAD (the European Institute of Business Administration) in Fontainebleau, France.

Mr Nissim Mashiach , Chief Operating OfficerNissim Mashiach has served as our senior vice president, operations since 2000 and was our plant manager from 1998 to 2000. From 1991 to 1998, he served in various production and operations management positions with Perio Products Ltd., a privately held medical devices manufacturer located in Jerusalem, Israel. Mr. Mashiach holds a B.Sc. in chemical engineering from the Technion in Haifa, Israel, an Mpharm.Sc. from the Hebrew University in Jerusalem, Israel and an M.B.A. from the University of Manchester.

Dr Harold Safferstein, Vice PresidentHarold Safferstein, Ph.D., J.D. has served as our vice president, business development since March 2006. From 2004 to 2005, he was executive vice president, corporate development for TransPharma Medical, Ltd. a privately held medical device company located in Israel. From 2001 to 2005, he was vice president, business development for Acorda Therapeutics, a CNS drug development and marketing company. From 1997 to 2001, he served in various business development and marketing positions with Bristol-Myers Squibb. From 1991 to 1997, he was director, technology transfer at the National Heart, Lung, and Blood Institute and cooperative venture manager for the National Institute of Allergy and Infectious Diseases, National Institutes of Health. Dr. Safferstein received a B.A. in biochemistry from Rutgers University, a Ph.D. in human anatomy and neurobiology from the University of Louisville, a J.D. from the American University, Washington College of Law and an M.B.A. from Columbia University.

Mr Michael Burshtine, Senior Vice President and Chief Financial OfficerMichael Burshtine has served as our senior vice president and chief financial officer since April 2004. From October 2001 to April 2004, he was the senior partner at Kesselman Corporate Finance Pricewaterhouse Coopers in Tel Aviv, Israel. From January 1999 to October 2001, he was an audit and transaction support partner at Kesselman & Kesselman Pricewaterhouse Coopers in Tel Aviv, Israel. From 1992 to 1999, he was a certified public accountant at Shachak Peer Reznick & Co. in Tel Aviv, Israel, including the last two years as a partner. Mr. Burshtine is a certified public accountant in Israel and has a B.A. in economics and accounting and an M.B.A. from Tel-Aviv University.

Mr Philippe Romagnoli, Vice President and SecretaryPhilippe Romagnoli has served as our vice president and secretary since April 2004. From September 2002 to April 2004, he was our interim chief financial officer and a member of our board of directors. Prior to joining OMRIX, from 1998 to 2002, he was the chairman of the board of Artesia Bank and from 1992 until 1998, the chief executive officer of Banque Paribas Belgium. Mr. Romagnoli holds an engineering degree with a specialty in physics from the University of Li`ege Belgium.


Össur hf.



Country Iceland

Website www.ossur.comEmail [email protected]

Address Grjothals 5

110 Reykjavik

Phone +354 5151300Fax +354 5151366

Ossur is a global orthopaedics company specializing in prosthetics, bracing and supports.

A leading provider of non-invasive orthopaedic products and services, Ossur is renowned for its pioneering work in the development, manufacture, sales and marketing of lower-limb prosthetics and a wide range of braces and supports. Heading up its long list of award-winning designs are the latest products from the Company’s Bionic Technology platform.

The continuing success of both its clinical and business achievements is underpinned by Ossur’s pro-active approach to building lasting partnerships with health professionals across the world. Aiming to be the principal source of innovative orthopaedic products and services, the Company harnesses the very best in design and technological advances in its constant pursuit of “Life without limitations”.

Ossur’s strategy is focused on maintaining its leading position within prosthetics and becoming a top-tier player within the orthopaedic fields of bracing and support products. A global operation is managed through a number of subsidiaries in North America, Europe and the Nordic region with a numerous distributors in other markets.

Technology/Product AdvantageNamed by the World Economic Forum as a "Technology Pioneer" for 2006, Ossur is the world’s second largest prosthetics manufacturer. A number of successful acquisitions have complemented its organic growth and enhanced its position as a major orthopaedics business. The consolidation and application of the Company’s core competencies, which include silicone, carbon fiber and its patented Bionic Technology, will fuel the growth of Ossur’s product portfolio and support its aim of becoming a market leader in its industry.

Ossur has continuously pushed the boundaries of prosthetic performance, enhancing mobility for amputees. Today it is extending its focus to braces and supports, applying new technologies and materials to improve clinical outcomes still further. By maintaining the current momentum and high levels of investment in R&D, as well as its collaborative efforts with universities and research partners, Ossur believes the Company will remain at the forefront of innovation.


Founded 1971


Business Activity

Key CustomersSouthern Prosthetic Suppl, Pacific Supply Co. Ltd, Beijing Reha Intl. Trade

Key PartnershipsVicthom Human Bionics , MIT

Key CompetitorsOtto Bock HealthCare GmbH, DJO Incorporated, Inc

Mr Hjörleifur Pálsson, Chief Financial OfficerEmail: [email protected]: +354 5151300

Presenter


Össur hf.



AchievementsA precise fusion of electronics, mechanics and human physiology forms the basis of Bionic Technology by Ossur. Partnering with the world’s most advanced technological organizations to restore maximum biological function to those in need, Ossur is expanding the bionic concept, escalating its use into the bracing and support arena. Intelligent devices already on the market: •The RHEO KNEE® - the first knee system to utilize the power of artificial intelligence, it learns and adapts automatically to the

individual walking styles. •The POWER KNEE™ - the world’s first powered prosthesis, it was honored by Popular Science magazine with a 2005 “Best of

What’s New” Award. It replaces true muscle activity to bend and straighten the knee as required. •The PROPRIO FOOT™ - the world’s first intelligent foot module provides unprecedented physiological benefits. It thinks for itself,

responding beautifully to changing terrain and transforming the approach to stairs and slopes.

Other informationOssur is keen to explore new business opportunities in China, particularly in the form of sales and distribution of its products via established companies in the region. The development of new partnerships in the fields of research, development and manufacturing are also of potential interest to this international non-invasive orthopaedics company.

Management TeamMr Jon Sigurdsson, Chief Executive Officer

Jon Sigurdsson, Ossur President and Chief Executive Officer, has lead the Company since 1996. He was the Commercial Counselor for the Icelandic Trade Council in New York between 1992 and 1996 and previously Chief Financial Officer at Álafoss 1989 – 1992. Mr. Sigurdsson also worked as Head of the International division of Eimskip (1986 – 1989) and as an Engineer for Bang and Olufsen Denmark (1982 – 1984). He is a board member of the Icelandic Trade Council, Icelandic Chamber of Commerce, Reykjavík University and Samherji, one of the leading fishery companies in Iceland. Mr. Sigurdsson has a B.Sc. degree in Industrial Engineering from Odense Technical College in Denmark and a Masters degree in Business Administration (MBA) from the United States International University in San Diego, US.

Mr Hjörleifur Pálsson, Chief Financial OfficerHjorleifur Palsson, Chief Financial Officer, joined Ossur in 2001. Before joining Össur he practiced as a Certified Public Accountant for 12 years. He was a partner at Deloitte from 1999 to 2001 and a partner at a local auditing firm from 1989 to 1999. Hjörleifur graduated in 1988 with a Business degree from University of Iceland and qualified as a Certified Public Accountant in 1989.

ShareholdersWilliam Demant Invest A/S 37%Others 20%Eyrir Invest ehf 15%Mallard Holding S.A 10%Vik Investment Holding S.a.r.l. 6%Kaupthing Bank hf 4%Lifeyrissjóður Verslunarmanna 3%Arion custodian account 2%Lífeyrissjóður Bankastræti 7 2%Landsbanki Islands 1%


2004 2005 2006 2007 2008201000155000Turnover2060025400EBIT

19100068400Equity690580 1180Employment


PamGene International B.V. B.V.



Country Netherlands

Website www.pamgene.comEmail [email protected]

Address P.O. Box 13455200 BJ 's-Hertogenbosch

Phone +31 736158080Fax +31 736158081

A European biotech company whose patented microarray technology supports drug development

Target markets are pharmaceutical and biotechnological research & development, clinical diagnostics, academia and research institutes.

PamGene’s 3 dimensional PamChip® Microarrays have 3 main applications:

The business model is to work in partnership for developing specific assays based on our microarray technology and where possible also in distributing instruments.

Technology/Product AdvantageThe search for drug compounds that act specifically against their target, with no effect on other inherent proteins, particularly benefits from this technology. The unique ability of PamGene’s technology to generate kinetic read-out of enzyme binding or protein-protein interactions has specific applications in:

1)Multiplex investigation of kinase pathways using cell-lysate and biochemical approaches.2)Testing the interaction of multiple nuclear receptors and co-regulators at one time

Additionally, PamGene’s platforms are suitable for nucleic acid analysis, specifically gene expression, genotyping, trisomy testing and SNP detection.


AchievementsPamGene's technology platform has a total of 31 granted patent families and patent applications worldwide

Founded 1999


Business Activity

Key CustomersJohnson&Johnson, Innogenetics, Check-Points, Olympus Corporation Ltd., Universities

Key PartnershipsInnogenetics, JPT GmbH, Olympus Corporation Ltd.

Key CompetitorsN.A.

Mr Tim Kievits, Chief Executive OfficerEmail: [email protected]: +31 6158080

Presenter


PamGene International B.V. B.V.



Financing Sought/Investment PlanPamGene International B.V. B.V. is seeking financing to a to be discussed amount in exchange for N.A..

N.A.

Management TeamMr Tim Kievits, Chief Executive Officer

Tim Kievits is CEO and founder of PamGene. Tim Kievits gained his degree in Chemistry in 1989 at Utrecht University, The Netherlands and started his professional career in 1985 in the department of Human Genetics at the University of Leiden, The Netherlands. In 1990 he joined Organon Teknika as pioneer in the NASBA nucleic acid amplification project and his research resulted in several patents. His final position at Organon Teknika (1999-2000) was Director Technology of the Nucleic Acid Diagnostics Business Area. In 2000 Kievits spun-off the microarray group for Organon Teknika and created PamGene.

Mr Theo van der Leij , Chief Operating OfficerChief Operations OfficerTheo van der Leij’s background is in Mechanical Engineering. His first job was with ICI where he became acting deputy plant manager. In 1993 he joined Organon Teknika and in his last position as Manufacturing Manager, he set up the FDAELA approved manufacturing and pilot production site for molecular biology based products and tripled production capacity.

Mr Rinie van Beuningen, Vice President Business DevelopmentRinie van Beuningen worked for 12 years at Organon Teknika as research scientist, product developer and project leader for new technologies. In 2001 he joined PamGene as co-founder and Vice President Technology where he is now responsible for IPR, applications and software and product development for PamChip® microarrays. His work has lead to successful implementation of PamGene’s microarray technology and its applications in Pharmaceutical R&D and out licensing to diagnostics companies.

ShareholdersAlta PartnersGIMVLife Science PartnersLa Compagnie Financière E. de RothschildOlympus Corporation Ltd.ManagementEmployeesPrivate shareholders


2004 2005 2006 2007 20083432Employment


Companyvaluation


1 12/2000 Startup / Early Stage Alta Partners; GIMV; Life Science Partners 60002 7/2003 Expansion / Development Alta Partners; GIMV; Life Science Partners; La Compagnie

Financière E. de Rothschild10000


Phytatec Ltd.




Website www.phytatec.comEmail

Address Unstead LaneGuildford GU5 0BT

Phone +44 1970823002Fax +44 197020212

Industrial Biotechnology

Short term target markets; Industrial enzymes,Mid term; Animal feed, focusing on aquacultureLong term; Oral vaccinesBusiness model; business to business, direct product sales and technology sub licencing

Technology/Product AdvantageThe companies Unique selling point is under pinned by proprietary plant based protein production technology. This couples the scalability associated with agriculture with the ability to produce a range of proteins at scale which are currently difficult to achieve with current technologies. Therefore as a market entry strategy the company has chosen to demonstrate the technologies viability by producing enzymes which are currently under supplied if supplied at all. The technology will it is believed expand the portfolio of enzymes that can be produced economically at scale.


AchievementsPatent filled covering Process;5 draft patents covering technology preparedProof of Concept completedMoving To Pilot scale production

Financing Sought/Investment PlanPhytatec Ltd. is seeking Startup / Early Stage financing to the amount of 0.38 M Euro in exchange for a to be discussed % of the company shares.

Working capital and levering grant aid

Founded 2002


Business Activity

Key CustomersPotential; Beldem, Universal Flavours

Key PartnershipsBiocatalyst Ltd, Medicago Inc, Cyclolab, Pan EU Research Network

Key CompetitorsDSM

Dr Steve Bowra, Chief Executive OfficerEmail: [email protected]

Presenter

Management TeamDr Steve Bowra, Chief Executive Officer

2003-date Principle founder, CEO/CSO of Phytatec (UK) Ltd2000-2003 Project Scientist, Danish Institute of Agricultural Sciences, Denmark1999-2000 Post Doc Fellow John Innes Center Norwich, UK1996-1999 Post Doc, Sembiosys, Canada

ShareholdersCo founders and Directors 100%


Phytatec Ltd.



Other informationThe finance sought will bedrawn as required, against strict milestones


2004 2005 2006 2007 2008138 1294 3929Turnover

-118 575 2983EBIT150 150 500Equity

1 7 12Employment


Companyvaluation


1 10/2002 Seed Private/Principle founder (150); Welsh Development agency Grant (56)

206


Primal Pictures Ltd




Website www.primalpictures.comEmail [email protected]

Address Tennyson House, 159-163 Great Portland StreetLondon W1W 5PA

Phone +44 2076371010Fax +44 2076367776

Digital education company

Primal Pictures is a new breed of digital education company. It has built a unique 3-D digital resource - a fundamental set of tools for alliedhealth students, doctors, healthcare companies, institutions, health professionals at every level, nurses, sports physicians, trainers - andpatients. Hundreds of colleges and medical schools, and hundreds of thousands of students currentlu use Primal''s resource as a core elementin their healthcare training.At the heart of Primal’s enterprise is the production of the world’s first complete 3-D computer graphic model of the human body. This unique contentcan be delivered online, or via CD-ROM or DVD. Primal Pictures began life as a research group, looking at techniques for creating high resolutiongraphics for medical teaching.Emerging from this research, Primal Pictures has now developed a set of key assets and underlying software tools which has resulted in a series ofCD-ROMs and online assets. Attention to detail and complete accuracy are the cornerstones of all Primal Pictures’ products. They are unsurpassed intheir completeness, resolution, and clarity. They have rapidly achieved the status of benchmarks in each area, andare used by the highest level medical professionals as a constant source of reference and education.The company now employs 31 staff in its Central London base and in USA. It has developed a core set of skills which involves the interpretation ofmedical imaging data, its processing into 3D models and its display as a coherent CAD-CAM model of anatomical structures. The companyessentially brings together knowledge of two technically advanced areas: 3D computer graphics (used in 3D computer animation andfeature films), and medical imaging technologies, such as Magnetic Resonance Imaging.

Founded 1991


Business Activity

Mr Laurie Wiseman, Managing DirectorEmail: [email protected]

Presenter

Management TeamMr Laurie Wiseman, Managing Director

Laurie Wiseman is a proven and award-winning innovator with a track record of initiating R&D and turning them into commercial successes. 22 years'' experience including the education, health, arts and traditional and new media sectors. Commercial acumen combined with creative drive. Built a world-leading technology and education business from scratch, raising a total of £5m for the venture, now into profit.Founded Primal Pictures with co-director, Chris Briscoe, a computergraphics expert.. Primal is now recognised as the world-leader in medical graphics, having earned a record five awards from the BritishMedical Association.Previously run TV producttion companies, and trained as a journlaist inUK. BA Degree in English from Cambridge University.


Primal Pictures Ltd



We wish to provide our software as an educational asset to medical schools and allied health programs in China. We are looking for government-level partners to enable us to disseminate our softaere in China.

Partnership Sought


Procter & Gamble



Country United States

Website www.pgbioscience.comEmail

Address 11810 East Miami River RoadOH 45252 Cincinnati

Phone +1 5139456364Fax

Industrial Biotech

Three billion times a day, P&G brands touch the lives of people around the world. The company has one of the strongest portfolios of trusted,quality, leadership brands, including Pampers(R), Tide(R), Ariel(R), Always(R), Whisper(R), Pantene(R), Mach3(R), Bounty(R), Dawn(R),Pringles(R), Folgers(R), Charmin(R), Downy(R), Lenor(R), Iams(R), Crest(R), Oral-B(R), Actonel(R), Duracell(R), Olay(R), Head & Shoulders(R), Wella, Gillette, and Braun. The P&G community consists of almost 140,000 employees working in over 80 countries worldwide. Please visit http://www.pg.com for the latest news and in-depth information about P&G and its brands.

Founded


Business Activity

Dr Darren X. Ji, Director of Bioscience Business Development, ChinaEmail: [email protected]: +1 5136270884

Presenter

Management TeamDr Darren X. Ji, Director of Bioscience Business Development, China

Darren Ji is the Director of Bioscience Business Development – East Asia of Procter & Gamble Company. Dr. Ji has the overall responsibility of identifying and managing deal transactions in bioscience-related technologies from Greater China, Japan and Korea for consumer product and pharmaceutical applications in the global market. Dr. Ji’s prior experiences included pharmaceutical R&D project and people management as well as managing multiple international partnerships in the US, Europe and Asia. He maintains an extensive and active business network and government relationship in the US, Greater China, Japan, and Korea.

Dr. Ji has been an invited speaker in major biotech/pharmaceuticalmeetings including the recent BioPartnering North America Vancouver,2006) and Bio2006 (Chicago, 2006) on topics of international businessdevelopment, and cross-fertilization of biotechnologies for pplicationsin pharma and non-pharma businesses.

Dr. Ji obtained his MD in Clinical Medicine, China Medical University,China (1986); PhD in Biotechnology, University of Sheffield, UK (1995); and MBA in Entrepreneurship and Economics, University of Chicago Graduate School of Business, USA (2005).

Dr. Ji’s past and current honors included President and Board Director of International Chinese Hard Tissue Society (USA), Guest Professorship of Nankai University and Chinese Academy of Sciences.

Dr André Convents, Section Head R&D EuropeDr. Andre Convents is currently Section Head for global technology development at Procter & Gamble Eurocor in Brussels. He leads a global team for Biotechnology development in Fabric and Home Care products. He joined P&G in 1990 where he spent half his career in P&G Eurocor on technology development and detergent product design and the other half in P&G Cincinnati, Ohio on technology and new detergent product development. His industrial experience covers a range of successful enzyme technology introductions in consumer products via strategic alliances. His experience covers management of multi-functional global teams as well as university and company joint collaborations in the European Union. Beside biotechnology, his experience in technology development covers polymers, surfactants, antimicrobials, builders, solvents, new-to-the-world product innovations and downstream product design.He is inventor on more than 20 patents and currently is portfolio manager of biotechnology strategic alliances. Dr. Andre Convents is a graduate from the Free University of Brussels, Belgium and followed a research program at the University for Arnhem, The Netherlands. Dr. Andre Convents is a graduate from the Free University of Brussels, Belgium and followed a research program at the University for Arnhem, The Netherlands. His academic research covered biochemical understanding of Adrenergic, Dopaminergic, Muscarine, G-proteins and Phosphokinase receptors in neurological tissue such as brains.


Procter & Gamble



For the following product categories that P&G has a business in, we are interested in collaborating/partnering on any technology or product thathas data supporting that it is better than, or has the potential to be better than current technologies or products.

1. Health and Medical Sciences

Pharmaceutical o Musculoskeletal o Gastrointestinal o “Women’s Health”

Non-pharmaceutical o Bone o Chemoreception o Dermatological - including Skin, Hair Follicles and Hair o Gastrointestinal o Inflammatory/Immune o Longevity/Anti-Aging (focus on pets) o Microbiology o Oral Care/Teeth/Gums o Pain o Respiratory o Uro-genital

2. Physical Sciences

•Cleaning Technologies (biological surfaces) •Cleaning and Drying Technologies (laundry and hard surfaces) •Diagnostic Devices •Food Technology/Processing •Materials Sciences/Formulation •Synthesis/Processing/Biotransformation •Water Purification

3. Capabilities

•Chemical/Natural Product Libraries and Databases •Clinical Capabilities •Drug Delivery/Product Delivery •Molecular Biology/Biochemistry Capabilities

Partnership Sought


ReNeuron Group plc




Website www.reneuron.comEmail [email protected]

Address 10 Nugent Road,Surrey Research Park

Guildford GU2 7AF

Phone +44 1483302560Fax +44 1483534864

Developer of stem cell therapeutics for major indications

ReNeuron is a world leading company focused on the development of novel stem cell therapeutics able to treat major unmet medical needs. Our leadproduct, ReN001, for which we intend to file an IND by the end of 2006, is a stem cell line to treat chronic stroke disability. ReN005 is a stem cell line for Huntington''s which is also preclinical. In the Research Stage are ReN002 for type 1 Diabetes, ReN003 for Retinal diseases and ReN004 for Parkinson's disease. ReNeuron has successfully partnered with both companies and universities to develop commercially viable stem cell therapeutics and drug discovery lines, using our proprietary stem cell platform, c-mycERTAM, which enables the efficient scale up of stem cells into stable, standardised and cGMP scalable stem cell products, able to treat all eligible patients without rederivation. Our partners and collaborators include Stem Cells Inc, Chemicon Inc, Harvard Medical School, Yale University (US), INSERM, France, CiL Biotech, Belgium, Regentec Ltd and Angel Biotechnology, UK.

Technology/Product AdvantageWe have a unique, proprietary and highly efficient stem cell expansion technology, c-mycERTAM. This platform enables, from a single tissue sample, the growth of selected human stem cells into banks of stable stem cell lines that are cGMP manufacturable. The process is fully regulated by way of a chemical safety switch so cell growth can be arrested before implantation. We produce stem cell lines to quality assured standards, enabling scale-up for clinical use without the need for re-derivation of those lines. Our stem cell lines can be frozen and thawed with very high viability, providing the basis for a dosage form for use in a clinical setting. We have also developed a unique screening platform using our c-mycERTAM technology that enables the selection of optimal stem cell lines for further development in the relevant disease indication. Selection criteria include cell phenotype, ability to expand into large-scale culture, and capacity to engraft, with minimal immune rejection.


Achievements•Exclusive license to c-mycERTAM platform technology•Further blocking patents on conditionally immortalized neural stem cells•Cell line patents extend protection across specific programs•Exclusive and non-competitive cross-license with StemCells, Inc. (NASDAQ: STEM), allowing access to extensive adult neural stem cell IP portfolio•Over 120 patents / patent applications worldwide

Founded 1997


Business Activity

Key CustomersLarge Pharma/biotech, SME biotech

Key PartnershipsStem Cells Inc, Chemicon Inc, Harvard Medical School, University of Pittsburgh, INSERM France, Kings College London

Key CompetitorsGeron, Stem Cells Inc

Dr John Sinden, Chief Scientific OfficerPresenter


ReNeuron Group plc



Other informationLooking for equity funding from investment institutions or strategic funding (which may include an equity stake) by corporate partners such as those looking to license ReNeuron's programmes for further development and commercialisation

Financing Sought/Investment PlanReNeuron Group plc is seeking Expansion / Development financing to a to be discussed amount in exchange for For negotiation.

General corporate purposes, including initial clinical trials of ReN001, or to fund specific therapeutic programmes, depending on the type of investor

ReNeuron is seeking collaborators in China for stem cell manufacturing, new stem cell technologies where scaleup technologies are required, clinical and scientific collaboration, territorial licenses to our products for the Chinese market, and any other collaborative/parnering opportunities.

Partnership Sought

Management TeamDr John Sinden, Chief Scientific Officer

Dr. Sinden is the Chief Scientific Officer, having been a director of the ReNeuron Group since October 1998. Dr. Sinden is a scientific co-founder of ReNeuron Limited. Prior to joining ReNeuron Limited as Chief Scientific Officer in October 1998, he was Reader in Neurobiology of Behaviour at the Institute of Psychiatry at Kings College London. He graduated in Psychology from the University of Sydney and completed a Ph.D. in Neuroscience from the University of Paris at the College de France. He subsequently held post-doctoral appointments at Oxford University and the Institute of Psychiatry prior to joining the permanent staff of the Institute in 1987.

Mr Michael Hunt, Chief ExecutiveMr. Hunt is the Chief Executive Officer, having been a director of the ReNeuron Group since January 2001. He joined ReNeuron Limited as Chief Financial Officer and was appointed Chief Operating Officer in September 2003 and Chief Executive Officer in July 2005. Prior to ReNeuron, he spent six years at Biocompatibles International plc where he held a number of senior financial and general management positions. His early industrial career was spent at Bunzl plc. He read economics at University College London and qualified as a chartered accountant with Ernst and Young in London.

ShareholdersMerlin Biosciences 48%Toscafield Ltd 11%StemCells Inc 9%Allianz Cornhill Insurance 3%INVESCO Asset Management 3%


2004 2005 2006 2007 200831 9Turnover

-3336-1253 -6773EBIT-10081841 4628Equity

1928 21Employment


Companyvaluation


1 1/1998 Startup / Early Stage Merlin General Partner Limited (7200)2 11/2000 Stock market listing Institutional Investors (2160) 650003 8/2005 Stock market listing Institutional Invesors (1368) 35000


RESprotect GmbH



Country Germany

Website www.resprotect.deEmail

Address Fiedlerstr. 3401307 Dresden

Phone +49 3514503200Fax +49 35145032010

Focusing on the inhibition of chemo resistance and the enhancement of chemo sensitivity

RESprotect GmbH is a privately owned biotechnology company located in Dresden Germany. RESprotect is focusing on the inhibition of chemoresistance and the enhancement of chemosensitivity. In contrast to the well known efforts to circumvent or decrease existing chemoresistance, this basic approach is unrivalled. RESprotect was founded in 2000. At present clinical studies with RP101 in the pancreas cancer indication, exploratory research in the identification of next generation of New Chemical Entities (NCEs) and general broadening of clinical indications are underway. RESprotect is in a position to enter exclusively a segment in the huge market of anticancer cytostatics.

Technology/Product AdvantageIn cancer model systems, chemoresistance is often mediated by a gsingle gene, and, therefore, may in theory be inhibited by any drug that targets the product of that gene. All these drugs possess potency and specificity exclusively for only one of the several reasons for chemoresistance. In contrast to this, RP101 affects numerous gene products related to chemoresistance and tumor immunity. In a phase I study including five different tumor entities and 12 different cytostatic drugs, no enhancement of unwanted side effects had been observed. In a phase II pilot study with 13 pancreas cancer patients, RP101 co-treatment enhanced remissions, survival and time to progression. The results of the pilot study were confirmed in a second study with 21 patients in similar stages of disease. The results were not identical but similar. Our two studies roughly showed the tendency to double the survival time.


AchievementsFraunhofer Prize 1999Central Germann Innovation Prize 2005

Founded 2000


Business Activity

Key PartnershipsA v a n t o g e n/LA/USA

Prof Rudolf Fahrig, Chief Executive OfficerEmail: [email protected]

Presenter

Management TeamProf Rudolf Fahrig, Chief Executive Officer

Professor for Genetics, University HamburgEducation and professional activity1972 - Managing Director of the „Central Laboratory forMutagenicity Testing“1974 - Habilitation at the Faculty of Biology of theJustus-Liebig-University Gießen for genetics: "Dose and effect ofmutagenic substances in vitro and in vivo"1978-1979 - Referee "Experimental research for testing of chemicals for carcinogenicity, mutagenicity and teratogenicity" of the FederalMinistry for Research and Technology, Bonn.1982 - 2000 - Head, Department of Genetics and Genetic Toxicology, Fraunhofer-Institute for Toxicology and Aerosol Research“, Hannover.1982-1994 - Deputy director, Institute for Toxicology and Molecular Biology (part of the„Fraunhofer-Institute for Toxicology and Aerosol Research“) 1983-1988 - Member, Editorial Board "Cell Biology and Toxicology"1983-1986 - Chairman, in vivo mammalian tests of the "IPCS collaborative study on short-term tests for genotoxicity and carcinogenicity" of the WHO 1984 - Habilitation, Faculty of Medicine, University Hamburg 1987 - President of the Workshop "The Spot Test with mice" of


RESprotect GmbH



RESprotect GmbH is seeking partnership for Other.

Licensing

Partnership Sought

the Environmental Mutagen Society of the U.S.A. in San Francisco/USA 1987 - "Joseph-von-Fraunhofer-Price" for the work "Genetichypothesis of tumor promotion and cocarcinogenesis“.since 1988 - Professor at the University Hamburg1988-1994 - President of the "Society for Environmental Mutation Research",the German speaking part of the "European Environmental Mutagen Society" (Germany, Austria, Switzerland)1989-1994 - Member of the German National Committee of the "International Union for Biological Sciences"since 1990 - Member, Editorial Board "Toxicology in vitro" 1991-1993 - Member of the programme committee of the „EuropeanEnvironmental Mutagen Society"1992 - President of the "22. Annual Meeting of the European Environmental Mutagen Society" in Berlin1998 - President of the "28th Annual Meeting of the European

ShareholdersP r o f . F a h r i g 54%F o n d s o f L B S a x o n y 27%A v a n t o g e n 10%F r a u n h o f e r S o c i e t y 9%


Shirat Enterprises Ltd.



Country Israel

WebsiteEmail

Address Weizmann Science Park, Bldg. 13APOB 31976102 Rehovot

Phone +972 89389965Fax +972 89300667

Venture Capitalist

Entrepreneur and venture capitalist with activities in China related to creation of Joint Ventures between Western and Chinese companies for commercialization of new products based on novel technologies developed by Western hi-tech companies. Management company for initiation and creation of the Joint Ventures between Western and Chinese companies.

Founded


Business Activity

Creation of Joint Ventures between Western companies which developed novel technologies and Chinese companies able to define and commercialize new products.

Partnership Sought

Mr Eliezer Manor, ManagerEmail: [email protected]: +972 505335901

Presenter

Management TeamMr Eliezer Manor, Manager

M. Sc. in Applied Physics – Weizmann Institute of Science, Israel.

13 years of experience in military R&D: Electro-Optics, Night Vision, Fire control, Special Forces. 5 years of experience in hi-tech entrepreneurship: night vision for Military and Para-military applications. 5 years of experience as Angel Investor in hi-tech start-up companies. 11 years of experience in parallel activities related to the following fields: Foundation and management of 2 Venture Capital (VC) Funds: in Israel and Silicon Valley and founder of IVA – Israel Venture Capital Association. Representation of large multinational companies for identification of novel technologies in Israel. Consultation to foreign Governments for establishments of hi-tech and VC industries. Board membership in private and public companies. Lecturer: hi-tech and VC in Israel and abroad. Venture Philanthropy on Community related activities


Tarilian Consulting Ltd




Website www.tarilian-consulting.com

Email [email protected]

Address 26 Valley ViewBarnetHertfordshire EN5 2NY

Phone +44 2084403507Fax +44 442084403507

Specialise in helping medical technology start-up early stage projects

At Tarilian, we specialise in helping medical technology start-ups and early stage projects to successfully achieve their full development potential and commercial success. Tarilian has expertise in research programme design and management, business planning and market modelling aswell as specific expertise in regulatory affairs and compliance, intellectual property management, clinical research and strategic management of research programmes within medical technology fields. Our website at www.tarilian-consulting.com provides a good overview of the structure of the Company and our approach.

Technology/Product AdvantageTarilian is currently engaged in seven main projects in the followingfields:

•Foetal Medicine and novel technologies •In-vitro diagnostic device development in chronic disease management •Cardiovascular medical device technology development; including the

development of a novel blood pressure monitor •Laser applications in Medicine •Investment Analysis and due diligence in specific Medical Technology

Investment Projects; currently Tarilian is engaged as advisors with twoMedTech investment portfolios. •MedTech Publishing •Medtech Investment Conferences

Founded


Business Activity

Dr Sandeep Shah, Managing DirectorEmail: [email protected]: +44 2084403507

Presenter


Tarilian Consulting Ltd



Our activity in technology development and commercialisation requires us to explore possible production and manufacturing links with China. Inaddition, we are advisors to life sciences investment funds; some of which are looking for new activity in China. This and our activities inBiotechnology and Medical Device development require us to develop international collaborations in these arenas.

We therefore welcome the opportunity to meet with other organisations that may operate within these domains.

We would like to meet other companies who are interested in research, productio, licensing and investment.

Partnership Sought

Management TeamDr Sandeep Shah, Managing Director

Dr Shah is the MD of Tarilian Consulting Limited, an international Medical Technology Development Consultancy. His practice concentrates on the strategic management of early stage MedTech development projects and includes a focus on business development and the funding of projects, product development consulting and technology transfer.

Dr Shah is also a Visting Lecturer in Health Technology to Brunel,Cranfield and Imperial Universities and a Senior Clinical Fellow of theHertfordshire PostGraduate Medical School. Dr Shah is also the Editor of The MedTech Business Review; an international Medical Technology Business Journal. Dr Shah is a frequent speaker at international events on MedTech development and MedTech commercialisation.

Following a successful career in Primary Healthcare, including inpreventative cardiology, Dr Shah held positions as Global Medical Director within the Medtech industry. In 2004, Dr Shah developed his own consultancy practice, Tarilian Consulting, which now has active medical technology development projects in USA, Asia and Europe. Tarilian is involved in the development of cardiovascular and respiratory devices, in-vitro diagnostics and novel biosensors. Tarilian is also currently involved in the development of new MedTech Research Parks; as well as national MedTech strategy development in various countries including in Asia. Tarilian Consulting have also been appointed as advisors to two MedTech investment funds.

Dr Shah has substantial experience of strategic development issues in the medical device industry. Dr Shah was a past Council Member of The Association of British Healthcare Industries and Member of the Funding and Reimbursement Group of Eucomed. He is also a member of the Device Committee of the British Institute of Regulatory Affairs and TOPRA, the European Regulatory Institute. He has served as a Standing Member of the Interventional Procedures Committee of the National Institute for Clinical Excellence and a WHO Cardiovascular Committee.


VASTox PLC Ltd




Website www.vastox.comEmail [email protected]

Address 91 Milton ParkAbingdon OX14 4RY

Phone +44 1235443901Fax +44 1235443999

VASTox is a chemical genomics company that discovers and develops proprietary new drugs

VASTox is a chemical genomics company that discovers and develops proprietary new drugs and provides a range of screening and chemistry services to the life sciences industry.

By applying its expertise and technology to research programmes licensed or acquired from academia, VASTox has established four drug discovery programmes. The company’s most advanced programme is focused on developing a new treatment for Duchenne Muscular Dystrophy based on the up-regulation of the protein utrophin. A second programme for Spinal Muscular Atrophy is also progressing rapidly, and two additional programmes focusing on multi-drug resistance (infectious diseases) and osteoarthritis have also been initiated.

VASTox’s technology platform uses Zebrafish (Danio rerio) and fruitflies (Drosophila melanogaster) which allows high-volume, high-content screening of small molecule drug candidates. This approach generates information that is highly predictive of efficacy and toxicity in humans, while having the potential to dramatically decrease the time and cost of drug discovery and development. It also allows the identification of secondary therapeutic indications for small molecules currently in development programmes.

VASTox was formed in January 2003 and has listed on the AIM segment of the London Stock Exchange in October 2004 (ticker: VOX). VASTox operates from a state of the art facility in Milton Park, near Oxford and currently employs over 40 staff.

Technology/Product AdvantageVASTox’s technology platform uses Zebrafish (Danio rerio) and fruitflies (Drosophila melanogaster) which allows high-volume, high-content screening of small molecule drug candidates. This approach generates information that is highly predictive of efficacy and toxicity in humans, while having the potential to dramatically decrease the time and cost of drug discovery and development. It also allows the identification of secondary therapeutic indications for small molecules currently in development programmes.


Founded 2001


Business Activity

Key CustomersRoche, Schering AG

Key PartnershipsMitsubishi Chemical

Dr Steven Lee, Chief Executive OfficerEmail: [email protected]: +44 1235443901

Presenter


VASTox PLC Ltd



AchievementsListed on the AIM segment of the London Stock Exchange in October 2004 (ticker: VOX). VASTox operates from a state of the art facility in Milton Park, near Oxford and currently employs over 40 staff.

Other informationPartnership Needs:Knowledge Partner

VASTox PLC Ltd is seeking partnership for Other.

Knowledge Partner

Partnership Sought

Management TeamDr Steven Lee, Chief Executive Officer

Steven has held a number of senior commercial and business development roles with major UK biotech companies: British Biotech plc, PA Consulting Group, Chiroscience Group plc and Datamonitor plc. From 2001 until 2004, Steven was Executive Director of Life Sciences at IP2IPO Group plc, the AIM quoted technology commercialisation specialist.

He has also acted as a consultant to multinational pharmaceutical companies on product strategy, working with Zeneca, Glaxo Wellcome, Novartis and Johnson & Johnson. His experience covers pharmaceutical R&D programme valuations, due diligence, M&A activity and expert reporting. Steven holds a PhD in parasite epidemiology from Kings College London.

ShareholdersListed company on London Stock Exchange: AIM


2004 2005 2006 2007 2008800 1500 5000 1500Turnover

8 45Employment


Companyvaluation


1 10/2004 Stock market listing 50000


Venture Valuation ltd



Country Switzerland

Website www.venturevaluation.comEmail [email protected]

Address Badenerstr. 188004 Zurich

Phone +41 433218660Fax +41 433218661

Independent third party valuation, assessment and monitoring of high growth companies

As an independent company focusing only on the valuation, assessment and monitoring we offer our services to investors as well as to the companies. Our Valuation Report and Valuation Radar provides a third party view. We are specialized in the area biotechnology (Novartis Venture Fund is a customer) and IT/e-commerce. We see the value of a company in its future potential. Zurich / Munich / Canada

Technology/Product AdvantageIndependent, standardized Valuation Report and Valuation Radar. Sophisticated valuation model based on scientific work at University St. Gallen and at EPFL Lausanne.


Founded 1999


Business Activity

Key CustomersNovartis Venture Fund, Fraunhofergesellschaft, European Investment Fund, Invision AG, many start-ups to pre-IPO

Key PartnershipsNovartis Venture Fund

Dr Patrik Frei, FounderEmail: [email protected]

Presenter


Venture Valuation ltd



AchievementsNovartis Venture Fund as key customer, high biotech competences with our office in Canada. We developed and run the Biotechgate (www.biotechgate.com) together with many country biotech databases:

www.austrianbiotech.comwww.canadianlifesciences.comwww.germanbiotech.comwww.indianbiotech.com www.frenchbiotech.comwww.italianbiotech.comwww.swisslifesciences.com

We are looking for companies that have financing needs and are interested in an independent valuations, or investors that would like to invest in Europe and need support in the evaluation and assessment of companies. Further more, we are interested in building up a chinesebiotech database and are looking for governmental and institutional partners.

Partnership Sought

Management TeamDr Patrik Frei, Founder


VerCell Biotechnology BV



Country Netherlands

WebsiteEmail

Address Drentestraat 24 BG, 1083 HK Amsterdam

Phone +7 4959812922Fax

VerCell Biotechnology BV is focused on the development of novel methods of xenotransplantation

We have developed a proprietary technology using cell xenotransplantation into polyacrylamide capsule.Our platform technology can be applied in andrology (male infertility), oncology, immunology, endocrinilogy.

Technology/Product AdvantageThe original technology developed by our researchers made it possible to overcome the main problem in transplantation of xenogenic cells into human organism, namely , tissue incompatibility. This way was achieved through the use of an inert polyacrylamide hydrogel “VITAGEL”, prepared in a special monomer-free substances. Being introduced into a recipient’s organism subcutaneously, VITAGEL forms a connective-tissue capsule (CTC). We are planning to use the formation of CTC as a platform technology for the treatment and prevention of diseases in endocrinology, andrology and oncology. The second invention is Polypeptide, the conjugate thereof with doxorubicine and a pharmaceutical composition based thereon. This invention will be extensively applied in practical oncology.The last inventions are test-systems to diagnose prostate cancer and S100, a test-system for diagnosing melanoma. They can be applied in practical oncology on a wider basis to diagnose cancer at an early stage or even at a precancerous stage.


AchievementsOur method of human melanoma xenogenic vaccination has successfully passed the first stage of clinical trials, and is going through the second stage of trials at the present time. Our method is protected by patents in Russia and international applications for patents in the USA, Australia, Belgium, Canada, Japan, China, Israel, Ukraine South Korea and European Union. Our technology can be applied not only for prophylaxis (vaccination) against immunogenic oncological diseases, but for treatment of these types of cancer at an earlier stage as well.

Founded 2002


Business Activity

Key CustomersHospitals

Ms Yulia Mozharenko, DirectorEmail: [email protected]

Presenter


VerCell Biotechnology BV



Management TeamMs Yulia Mozharenko, Director

Ms. Yulia Mozharenko is a Director of VerCell Biotechnology BV, a corporation incorporated under the laws of The Netherlands.She has a Masters Degree with specializations in Civil Law, Civil Procedure, Private International Law, and numerous international training courses in Harvard Law School, Duke University, and Columbia University with specialization in Taxation problems and corporate finance for layers and economists.Ms. Mozharenko has over fifteen years of business experience working with private companies and government organizations including Russian Joint Stock Company “United Energy Systems of Russia”, Federal Energy Commission (FEC) of the Russian Federation, Investment Bank “Renaissance Capital”, Adidas Closed Joint Stock Company.

Mr Sergei Vlassov, Project DirectorMr. Sergei Vlassov, Project Director Mr. Vlassov joined VerCell as a Project Director, to be responsible for the company’s product development and commercialization strategy, in November 2005.He has a Masters of Science in Biochemistry and a Masters Degree in Marketing from leading Russian universities. He also holds a Post Graduate Certificate in Management from University of Kingston UK. Mr. Vlassov has over fifteen years of pharmaceutical industry experience in marketing, business development management and consulting positions. Scientific background includes seven years as a researcher in biotechnology.For Wyeth-Ayerst Canada Inc. he was the Manager, Market Planning responsible for developing and implementing of new products’ strategies in different therapeutic categories. For SmithKline Beecham International (UK, HQ) he was the Project Manager responsible for all aspects of a process organization of a joint venture company between SKB and Eastern European vaccine manufacturing company. He has led product development, marketing and sales teams resulting in dramatic sales increase.


Life Sciences Company Profileold.iss.it/binary/biot/cont/all.1200910092.pdf · business management...

Documents

Transcript of Life Sciences Company Profileold.iss.it/binary/biot/cont/all.1200910092.pdf · business management...